Biotechnology News and Information. Includes Arizona Biotechnology, Arizona Biotech news, genomics, biotech companies, genetic engineering, biotech research, biology and biological technology news and information.

BioTech News at Arizona Biotech

Biotech News <<< Mailing List

Biotechnology News <<< Discussion Forums

This site is a member of WebRing.
To browse visit Here.

Thursday, June 30, 2005

[ biotech news ] Millennium Announces New CEO

Millennium Announces New CEO

-- Head of Novartis North American Oncology Business to drive
Millennium toward long-term growth and near-term profitability --

Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM - News) today
announced that Deborah Dunsire, M.D., an accomplished pharmaceutical
executive and head of Novartis Pharmaceuticals Corporation's North
American Oncology Operations, has been named as the new president
and chief executive officer of Millennium. Dr. Dunsire will also be
elected to the Company's Board of Directors. She plans to assume her
duties by August 1, 2005. Dr. Dunsire will succeed Mr. Mark Levin,
co-founder and CEO since the Company's inception. Mr. Kenneth Weg, a
member of the Board of Directors since 2001, will become the new non-
executive chairman. Mr. Levin will remain an active member of the
Board.

"Deborah has an impressive track record in building and motivating
multi- functional organizations to deliver significant revenues and
sustainable growth, two key goals for Millennium," said Mr.
Weg. "Her depth of experience and proven leadership in the
pharmaceutical industry and repeated success in commercializing
products will enable Millennium to optimize the potential of its
novel therapies and capitalize on the Company's strengths in
innovative drug discovery and development."

Dr. Dunsire has nearly 20 years of experience in the commercial,
operational, clinical and scientific aspects of a world-leading
pharmaceutical business. She led the Novartis U.S. Oncology Business
in a competitive market, achieving more than 25 percent compounded
annual growth rate over the last eight years. While at Novartis, Dr.
Dunsire also played a critical role in the broad development and
successful launch of a number of products including Zometa, Femara
and Gleevec, and evaluated and implemented key business development
initiatives. She was also responsible for managing the merger and
significant growth of the combined Sandoz Pharmaceuticals and Ciba-
Geigy oncology businesses.

"Millennium is poised for continued growth and I'm excited to be
joining at such a pivotal point in the Company's development," said
Dr. Dunsire. "Widely recognized for scientific leadership,
entrepreneurial culture and visionary management, Millennium can
command a strong commercial presence and leverage its robust product
pipeline. I look forward to building on the Company's rich legacy
and track record in bringing breakthrough medicines to patients,
while fulfilling its goal of non-GAAP profitability in 2006 and long-
term growth."

Dr. Dunsire has served on the U.S. pharmaceutical executive
committee at Novartis, was a designated member of the corporate
executive group, and a member of the operating committee charged
with defining corporate strategy, managing operations and assessing
executive performance.

Earlier in her career, Dr. Dunsire was a clinical researcher
responsible for the implementation of global phase II and phase III
studies across multiple therapeutic areas such as immunology,
endocrinology, neurology, dermatology, oncology and transplantation.
She has also been a practicing physician.

"Deborah shares an unwavering commitment to making a difference in
patients' lives, the Company's mission since day one," said Mark
Levin. "She is dedicated to building a leading biopharmaceutical
company and has the commercial and business experience to make it
happen for our stockholders, employees, partners and patients."

Acknowledging the exceptional contributions of Mark Levin, Mr. Weg
stated, "Mark has been one of the great visionaries in the biotech
industry and his passion for the business, amazing energy and
ability to motivate people at Millennium has been no less than
remarkable. I would like to express the Board's sincerest
appreciation for Mark's dedication to the Company over the past 12
years, his commitment to patients to deliver breakthrough medicines,
and his promise to build value for shareholders."

Mr. Weg has had more than 30 years of experience in the
pharmaceutical industry including significant leadership roles at
Merck & Co., Inc. and Bristol-Myers Squibb Company (BMS). At BMS he
was elected to the Board of Directors in 1995 and became vice
chairman in 1999. He also served as president, Worldwide Medicines
Group; president, Pharmaceuticals Group; and president of
Pharmaceutical Operations. Currently, Ken is chairman of Clearview
Projects, a consulting firm which provides partnering and
transactional services to biopharmaceutical companies and academic
institutions.

Conference Call Information

In conjunction with this news release, Millennium will host a live
webcast of its conference call today, Wednesday, June 29, 2005 at
8:00 AM ET. This webcast can be accessed by visiting the Investors
section of the Company's website, http://www.millennium.com.
Following the webcast, an archived version of the call will be
available at the same address for 30 days.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical
company based in Cambridge, Mass., markets VELCADE® (bortezomib) for
Injection, a novel cancer product, co-promotes INTEGRILIN®
(eptifibatide) Injection, a market-leading cardiovascular product,
and has a robust clinical development pipeline of product
candidates. The Company's research, development and
commercialization activities are focused in three therapeutic areas:
oncology, cardiovascular, and inflammation. By applying its
knowledge of the human genome, its understanding of disease
mechanisms, and its industrialized drug discovery platform,
Millennium is seeking to develop breakthrough products.

This press release contains "forward-looking statements," including
statements about the Company's growth, discovery and development of
products and financial results. Various important risks may cause
the Company's actual results to differ materially from the results
indicated by these forward- looking statements, including: adverse
results in its drug discovery and clinical development programs;
failure to obtain patent protection for its discoveries; commercial
limitations imposed by patents owned or controlled by third parties;
the Company's dependence upon strategic alliance partners to develop
and commercialize products and services based on its work;
difficulties or delays in obtaining regulatory approvals to market
products and services resulting from its development efforts;
product withdrawals; competitive factors; difficulties or delays in
manufacturing the Company's products; government and third party
reimbursement rates; the commercial success of VELCADE and
INTEGRILIN; achieving revenue consistent with internal forecasts;
and the requirement for substantial funding to conduct research and
development and to expand commercialization activities. For a
further list and description of the risks and uncertainties the
Company faces, see the reports it has filed with the Securities and
Exchange Commission. The Company disclaims any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Organon Launches Global Research and Biotechnology Initiative

Organon Launches Global Research and Biotechnology Initiative

- Organon's Biotechnology Day Attracts Over 100 Boston-area
Biotechnology and Licensing Executives -

Organon, the human healthcare business of Akzo Nobel (Nasdaq: AKZOY -
News), announced that the Company is launching a global
biotechnology discovery research initiative with a Boston seminar
and open house to discuss R&D strategy and collaborative
opportunities.

"Organon is expanding upon its current biotechnology programs with a
global discovery research initiative aimed at diversifying our
therapeutic areas of focus and bringing the next generation of
biopharmaceutical products to market," stated David Nicholson,
Executive Vice President Global Research at Organon. "Organon
fosters innovation and entrepreneurship with its unique approach to
discovery research by giving our scientists the ability to explore
interesting targets and compounds without being restricted to a
specific therapeutic area of focus. When successful, our global
pharmaceutical operations will provide the infrastructure and know-
how needed to rapidly find an appropriate partner or move promising
new programs towards the market."

Organon's strategy in biotechnology is to develop and market
biological entities that represent new therapeutic approaches within
areas of interest including immunology, oncology and osteoporosis.
Organon will leverage its proprietary monoclonal antibody technology
and is committed to partnering with academia for early research, and
with biotechnology and pharmaceutical companies for product
development programs and for access to the best discovery
technologies. The new Cambridge research center, which officially
opened on June 29th, will be the hub of its interface with
innovative institutes and companies in the USA.

Organon's Biotechnology Day, that has attracted over 100 local
biotechnology and licensing executives, will include discussions of
Organon's research and partnering strategy by members of Organon's
senior management including Toon Wilderbeek, President of Organon
International; David Nicholson, and Wiebe Olijve Ph.D., Vice
President Research at Organon. Additional talks will focus on doing
business with Organon from Mark Gessler, CEO and President of Gene
Logic Inc.; Aaron Hsueh, Ph.D., Professor at Stanford University;
and Arthur Sands, M.D., Ph.D., CEO and President of Lexicon Genetics.

Organon and Biotechnology

Organon and its sister businesses in Diosynth Biotechnology and
Intervet have a strong heritage in biotechnology. Organon's
capabilities cover all aspects of drug discovery and development,
from early research through clinical development and large scale
manufacturing. The companies are actively involved in developing
recombinant fertility treatments (Organon), recombinant vaccines
(Intervet) and recombinant protein API's (Diosynth Biotechnology).
Organon's lead product today is the biologic Follistim® (USA),
Puregon® (Europe) and biotech now represents over 20% of revenues.
Organon is also one of the largest global contract manufacturers of
Active Biopharmaceutical Ingredients through Diosynth Biotechnology.

Research at Organon

Organon has a strong commitment to research and development with
approximately 19% of revenues budgeted annually to R&D. The Company
maintains discovery research facilities in Oss, The Netherlands;
Newhouse, Scotland; and Cambridge, Mass., USA. Research programs
encompass both biotherapeutic and small molecule discovery with over
20% of budgets committed to external collaborations. Current
discovery collaborations involve over 50 biotech and academic groups
worldwide. The new Organon Research Center in Cambridge will
discover novel biologicals and will be the hub of interface with
innovative institutes and biotechnology companies in the USA.

About Organon

Organon -- with shared head offices in Roseland, NJ, USA and Oss,
The Netherlands -- creates, manufactures and markets prescription
medicines that improve the health and quality of human life. Through
a combination of independent growth and business partnerships,
Organon strives to remain or become one of the leading
pharmaceutical companies in each of its core therapeutic fields:
reproductive medicine, psychiatry and anesthesia. Organon also
actively pursues the discovery of both chemical and novel biological
entities. In so doing, Organon seeks to exploit and further develop
its basic discovery and production expertise in biotechnology.
Organon products are sold in over 100 countries, of which more than
60 have an Organon subsidiary. Organon is the human health care
business unit of Akzo Nobel. Additional information about Organon is
available through its corporate website, http://www.organon.com.

For more information
Contact for Organon:
Monique Mols Kari Lampka
Associate Director, Media Relations MacDougall Biomedical
Communications
+31-(0)412-665440 +1-508-647-0209
klampka@macbiocom.com

---------------------------------------------------------------------
-----------
Source: Organon

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Biotechnology Companies Have to Insure against Failures in the Research & Develo

Biotechnology Companies Have to Insure against Failures in the
Research & Development Stages

Both biotechnology and pharmaceutical companies are feeling the
pressure created by the immense hype around the biotechnology
industry. Its extraordinary popularity creates unreasonable
expectations, wherein even common molecule failure in the research
and development (R&D) stages result in loss of both investor
confidence and funds for further research.

Such unrealistic expectations can be especially crippling to new
companies. The biotechnology sector will suffer more than
pharmaceuticals, as it does not have many established companies that
can absorb the burden of failed ventures.

If you are interested in a virtual brochure, which provides
manufacturers, end users, and other industry participants with an
overview of the Cost Benefit Analysis of Research and Development of
Top 10 Biotechnology Companies, then send an e-mail to Melina
Gonzalez, Corporate Communications, at melina.gonzalez@frost.com,
with the following information: your full name, company name, title,
telephone number, fax number, and e-mail address. Upon receipt of
the above information, an overview will be sent to you through e-
mail.

As a drug moves through more advanced stages of R&D, the losses
associated with failure will tend to naturally increase. To counter
this situation, biotech companies could enter into licensing deals
and implement risk management solutions.

The industry trends point toward an increase in such deals and
partnerships between companies. By sharing the risks and profits,
they can eliminate or decrease the jeopardy associated with
failures.

"The partnerships between big pharma and biotech companies are
likely to be the trendsetters in the industry," says Frost &
Sullivan Research Analyst Barath Shankar S. "With the technical
expertise of biotechnology companies and the marketing skills of big
pharmas, the collaborations are expected to be very successful."

Such strategic moves and plans have seen the top ten biotechnology
companies in the United States have 186 products in R&D, and of
these, nearly 20 percent are in phase III of development. These
products are likely to have substantial impact on market growth in
the next two to three years.

The biotechnology industry is optimistic about market growth despite
the recent spate of drug recalls, which wiped out billion's of
dollars of market capital. Since the fundamentals of product
development are sound, the companies are confident of overcoming
these setbacks and accelerating growth.

This positive attitude is a huge advantage in the biotechnology
industry, since it thrives on risk taking. From 1994 to 2005, the
top ten companies have returned an exceptional figure of close to 27
percent on stock price appreciation. In the next year, this number
is expected to reach 24-25 percent, despite a few setbacks.

Established companies such as Amgen, Chiron, Genentech, and Genzyme
are expected to continue leading the market. Such high returns from
biotechnology stocks are likely to sustain investor interest in the
industry and maintain focus on new R&D projects.

"Biogen IDEC, which has delivered the highest returns of 43.5
percent from 1994 to 2005, has a risk rating of 'moderate/high',"
says Barath Shankar. "Similarly, Gilead which has returned 29.5
percent, much above the industry average, has the highest risk
rating of 'very risky'."

Cost Benefit Analysis of Research and Development of Top 10
Biotechnology Companies is part of the pharmaceuticals and clinical
diagnostics subscription and examines the risk-return and cost-
benefit profiles of research and development of the top ten
biotechnology companies in the United States. The study incorporates
a model to evaluate and provide an outlook for each of these
companies. It also analyzes the possible blockbuster products in the
product pipelines. Analyst interviews are available to the press.

Frost & Sullivan, a global growth consulting company, has been
partnering with clients to support the development of innovative
strategies for more than 40 years. The company's industry expertise
integrates growth consulting, growth partnership services and
corporate management training to identify and develop opportunities.
Frost & Sullivan serves an extensive clientele that includes Global
1000 companies, emerging companies, and the investment community, by
providing comprehensive industry coverage that reflects a unique
global perspective and combines ongoing analysis of markets,
technologies, econometrics, and demographics. For more information,
visit http://www.frost.com

Cost Benefit Analysis of Research and Development of Top 10
Biotechnology Companies

F246

Keywords in this release: biotech companies, cost benefit analysis,
research and development, R&D, United States, Amgen, Chiron,
Genentech, Genzyme, Biogen IDEC, research, information, market,
trends, technology, service, forecast, market share

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Governor signs executive order declaring N.M. a biotechnology leader - 2005-06-24

Governor signs executive order declaring N.M. a biotechnology leader - 2005-06-24

Governor signs executive order declaring N.M. a biotechnology leader

NMBW Staff

Governor Bill Richardson has signed a proclamation declaring New Mexico a world leader in biotechnology research and development, and in the development of related industry clusters.

It directs that all cabinet departments, agencies, public schools, and public hospitals of the state of New Mexico provide assistance when requested by the New Mexico Department of Economic Development's Office of Science and Technology and acknowledges that the NMEDD has developed a statewide plan for biotechnology research and development, a release from the NMEDD says.

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Thomas H. McLain Appointed to the Biotechnology Industry Organization's Board of

Thomas H. McLain Appointed to the Biotechnology Industry
Organization's Board of Directors

Nabi Biopharmaceuticals (Nasdaq: NABI - News) announced today that
its chairman, chief executive officer and president, Thomas H.
McLain, has been appointed to the Board of Directors of the
Biotechnology Industry Organization (BIO), effective June 21, 2005.
Mr. McLain is one of eleven new Board members, who will each serve
two-year terms.

BIO represents more than 1,000 biotechnology companies, academic
institutions, state biotechnology centers and related organizations
in all 50 U.S. states and 33 other nations. BIO members are involved
in the research and development of healthcare, agricultural,
industrial and environmental biotechnology products.

"Biotechnology's impact on human health has never been greater; its
discoveries are beginning to realize their great promise. I am
honored to accept this Board position, as our industry continues to
serve as a leading force in the advancement of 21st century
medicine," said Mr. McLain.

Mr. McLain joined Nabi Biopharmaceuticals in 1998 and today serves
as chairman, chief executive officer and president of the company.
From 1988 to 1998, Mr. McLain was employed by Bausch & Lomb,
Incorporated. He earned his B.A. in Economics at College of the Holy
Cross and an M.B.A. from the William E. Simon Graduate School of
Business at the University of Rochester. He is a member of the Board
of Directors of Eastman Chemical Company and serves as the Chairman
of BioFlorida.

"Tom McLain is a widely recognized leader in the emerging life
sciences arena both nationally and internationally," said Florida
Governor Jeb Bush. "As Florida is increasingly positioned at the
epicenter of this industry, we are fortunate to have someone of
Tom's caliber contributing on a national scale. I applaud BIO's
decision to recognize Tom's commitment to and noted achievements in
biotechnology, and look forward to his ongoing leadership to escort
the industry to new heights."

"Tom McLain's knowledge, experience and vision make him an ideal
addition to our Board of Directors," said BIO President James
Greenwood. "In particular, we value his expertise in vaccines and
his role in the emergence of biotech in Florida."

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in
powering the immune system to develop and market products that fight
serious medical conditions. We are poised to capture large,
commercial opportunities in our four core business areas: Gram-
positive bacterial infections, hepatitis, kidney disease
(nephrology), and nicotine addiction. We have three products on the
market today: PhosLo® (calcium acetate), Nabi-HB® [Hepatitis B
Immune Globulin (Human)], and Aloprim(TM) [Allopurinol sodium (for
injection)] and a number of products in various stages of clinical
and preclinical development. The company filed its Marketing
Authorization Application in Europe for its product candidate,
StaphVAX® [Staphylococcus aureus Polysaccharide Conjugate Vaccine],
in December 2004. The application was accepted for review in January
2005. StaphVAX is currently in a confirmatory Phase III clinical
trial in the U.S. StaphVAX is designed to prevent the most dangerous
and prevalent strains of Staphylococcus aureus bacterial infections.
S. aureus bacteria are a major cause of hospital-acquired infections
and are becoming increasingly resistant to antibiotics. The
company's other products in development include Altastaph(TM)
[Staphylococcus aureus Immune Globulin Intravenous (Human)], an
antibody for prevention and treatment of S. aureus infections, NicVAX
(TM) [Nicotine Conjugate Vaccine], a vaccine to treat nicotine
addiction, and Civacir(TM) [Hepatitis C Immune Globulin (Human)], an
antibody for preventing hepatitis C virus re-infection in liver
transplant patients. For additional information on Nabi
Biopharmaceuticals, please visit our website at:
http://www.nabi.com .

This press release contains forward-looking statements that reflect
the company's current expectations regarding future events. Any such
forward- looking statements are not guarantees of future performance
and involve significant risks and uncertainties. Actual results may
differ significantly from those in the forward-looking statements as
a result of any number of factors, including, but not limited to,
risks relating to the possibility that our confirmatory Phase III
clinical trial for StaphVAX or our plans to commercialize StaphVAX
in the European Union and United States may not be successful; the
possibility that we may not realize the value of our acquisition of
PhosLo; the company's ability to raise additional capital on
acceptable terms; the company's dependence upon third parties to
manufacture its products; the company's ability to utilize the full
capacity of its manufacturing facility; the impact on sales of Nabi-
HB from patient treatment protocols and the number of liver
transplants performed in HBV-positive patients; reliance on a small
number of customers; the future sales growth prospects for the
company's biopharmaceutical products; and the company's ability to
obtain regulatory approval for its products in the United States or
abroad or to successfully develop, manufacture and market its
products. These factors are more fully discussed in the company's
Annual Report on Form 10-K for the fiscal year ended December 25,
2004 filed with the Securities and Exchange Commission.

---------------------------------------------------------------------
-----------
Source: Nabi Biopharmaceuticals

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Cougar Biotechnology Licenses Rights to Seocalcitol from LEO Pharma

Cougar Biotechnology Licenses Rights to Seocalcitol from LEO Pharma

Cougar Biotechnology, Inc., a privately held biotechnology company,
today announced that it has licensed the worldwide, exclusive rights
to seocalcitol (EB1089) from LEO Pharma A/S (Ballerup, Denmark).
Seocalcitol (EB1089) is a synthetic analog of vitamin D (1-alpha,25
(OH2)D3) that has been clinically tested in a number of different
cancer indications.

The results of in vivo and in vitro studies have shown that vitamin
D and analogs of vitamin D have anticancer activity in a wide range
of tumor types. The results of preclinical studies have shown that
seocalcitol (EB1089) is 50-200 times more potent than 1-alpha,25(OH2)
D3 with respect to regulation of cell growth and differentiation in
in vitro and in vivo tumor models. Importantly, because seocalcitol
has shown reduced calcemic activity compared to 1-alpha,25(OH2)D3,
this increase in antitumor activity is seen without inducing
unacceptable levels of hypercalcemia.

"Vitamin D analogs represent an emerging class of potentially
promising drugs for the treatment of prostate cancer," said Dr. Arie
Belldegrun, MD, FACS, Vice Chairman of the Board of Directors of
Cougar Biotechnology. "Based on the preclinical and clinical studies
that have been completed with seocalcitol (EB1089), we believe that
the drug may represent a potentially novel treatment option for
patients with hormone refractory prostate cancer."

"We are pleased to be able to complete this licensing agreement with
LEO Pharma," said Alan H. Auerbach, chief executive officer and
president of Cougar Biotechnology. "Seocalcitol (EB1089) is the
third drug that Cougar has in-licensed since the company was founded
approximately two years ago. We view it as an important addition to
Cougar's pipeline and as an intriguing new potential treatment for
prostate cancer."

Under the terms of the licensing agreement, LEO Pharma received an
upfront payment and will receive milestone payments as seocalcitol
progresses through clinical development as well as a royalty on
sales. Detailed financial terms were not disclosed.

About Cougar Biotechnology

Cougar Biotechnology, Inc. is a Los Angeles-based private
biotechnology company established to in-license and develop clinical
stage drugs, with a specific focus on the field of oncology.
Cougar's oncology portfolio includes CB7630, which has completed
Phase I clinical trials in prostate cancer, and CB3304, which is
currently being tested in a Phase I trial in non-Hodgkin's lymphoma.
Further information about Cougar Biotechnology can be found at
www.cougarbiotechnology.com.

About LEO Pharma A/S

LEO Pharma A/S is a research-based, fully integrated pharmaceutical
company among the world's leading players in topical dermatology and
parenteral treatment of thrombotic disorders. The foundation-owned
company is headquartered in Denmark, markets its products in 90
countries and employs 3,300 people in 40 countries. Further
information about LEO Pharma can be found at www.leo-pharma.com.

Contact Cougar Biotechnology, Inc. Alan H. Auerbach, 310-443-4209

http://www.arizonabiotech.com/
Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
Biotech News
http://www.arizonaentrepreneurs.com/
Arizona Entrepreneurs
http://www.azhttp.com/
Arizona High Tech
Biotechnology News Forums

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Mayo Clinic research site joining biotech corridor

Mayo Clinic research site joining biotech corridor

Mayo Clinic research site joining biotech corridor

Kate Nolan
The Arizona Republic
Jun. 30, 2005 12:00 AM

SCOTTSDALE - Brainiacs in Scottsdale, rejoice.

An 110,000-square-foot research building, 70 percent of it laboratories focused on curing cancer, opens with an event at 8:30 a.m. today at Mayo Clinic in Scottsdale, 13400 E. Shea Blvd.

It is the second of three research structures planned for the site. advertisement

The three-story, $29 million Collaborative Research Building represents a new doorway along Shea Boulevard's growing biotech corridor and a step toward more robust collaboration within the Valley's developing biotech network.

Researchers from the Mayo Clinic Cancer Center, Translational Genomics Research Institute (TGen), and Arizona State University are already in various stages of settling into lab space at the new site.

Top research facilities were crucial in attracting those potential collaborators as well as recruiting Mayo researchers, said Dr. Laurence Miller, director of Mayo's cancer center, who oversaw the scientific end of the project.

Its research benches ultimately will fill huge open spaces on two floors where entire teams can work together, unlike outdated labs where space is carved out of smaller rooms.

Biotech News

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Wednesday, June 29, 2005

[ biotech news ] Molecular Profiling Institute, Inc. Acquires NanoBiomics, Inc.

Molecular Profiling Institute, Inc. Acquires NanoBiomics, Inc.

Developing a platform to commercialize novel genomics-based products

06-29-2005

Phoenix, AZ, June 29, 2005The Molecular Profiling Institute, Inc.
(Molecular Profiling) today announced the acquisition of the assets
of NanoBiomics, Inc. NanoBiomics is an early-stage company whose
mission is to develop and commercialize genomic-based diagnostics
utilizing nanoscale-processing technologies created at the Applied
Nanobioscience Center at ASU. Nanobiomics was recently recognized as
the "Startup Biotechnology Company of the Year" from the Arizona
BioIndustry Association at the Arizona Bio Expo 2005.
NanoBiomics was formed by the Translational Genomics Research
Institute (TGen) and Arizona Technology Enterprises (AzTE) with the
intention to commercialize technology from both organizations.
Molecular Profiling, a collaboration between TGen and the
International Genomics Consortium (IGC), is a specialty reference
laboratory and a leader in using genetic signatures to help tailor
medical therapy. Molecular Profiling is the first for-profit spin-
off venture for TGen and IGC.

"The acquisition provides Molecular Profiling with a platform for
commercializing novel, genomic-based diagnostic products in the
future," said Richard Love, acting president of NanoBiomics and
Managing Director of TGen Accelerators. "Molecular Profiling is
currently driving physician adoption of such tests in the reference
lab setting. As these tests are accepted into the practice of
medicine, NanoBiomics' technologies will help enable lower cost
diagnostic products to be produced and commercialized more broadly."

Molecular Profiling will work closely with Dr. Frederic Zenhausern,
Director of the Applied Nanobioscience Center at ASU's Biodesign
Institute. "Dr. Zenhausern is a pioneer in using nanoscale
processing technologies to perform complex biological processes on
cartridges the size of credit cards," said Dr. Robert Penny, CEO of
Molecular Profiling. "These technologies will ultimately drive down
the cost of genomic-based diagnostic testing and this transactions
will provide a commercial focus for the collaboration to enhance the
collaboration between TGen, IGC and ASU at Molecular Profiling."

According to Zenhausern, "The goal of developing the technologies
behind NanoBiomics is to be able to one day provide better
diagnostic platforms for physicians to better diagnose and treat
complex diseases."

The acquisition brings together the diagnostic platform developed by
ASU, the diverse and extensive database of DNA signatures and
scientific leadership from TGen, and the reference laboratory
expertise and market access offered by Molecular Profiling.

"The complementary technologies that Molecular Profiling, TGen and
NanoBiomics bring to bear create a stronger molecular diagnostics
products and services company with a clear commercialization path,"
said Peter Slate, the CEO of AzTE. "This is a case where the sum is
worth substantially more than the individual parts."

The terms of the acquisition have not been disclosed.

# # #

About the Molecular Profiling Institute Inc.
The Molecular Profiling Institute, Inc. (Molecular Profiling) is a
specialty reference laboratory that helps cancer patients worldwide
by applying the discoveries of the Human Genome Project to
personalized medicine. Molecular Profiling provides cutting-edge
testing facilities, products, and resources for genomic and
proteomic profiling and treatment of cancers. Molecular Profiling
has strategic relationships and alliances with the Translational
Genomics Research Institute (TGen), the International Genomics
Consortium (IGC), IBM and AmeriPath.

About NanoBiomics, Inc.
NanoBiomics' mission is to improve healthcare by developing
molecular diagnostics that increase the physician's ability to
accurately determine the medical diagnosis and medical prognosis of
the patient. NanoBiomics targets the rapidly growing field of
molecular diagnostics. The company's primary focus is the
commercialization of molecular diagnostics based primarily upon gene
expression signature sets that offer substantial predictive or
prognostic value for disease outcome. The value gained from these
diagnostics will be to increase the survival rates of patients by
tailoring the therapeutic regiment to the genomic profile of a
disease.

About Arizona Technology Enterprises
Arizona Technology Enterprises at Arizona State University works
with university inventors and industry to transform scientific
innovations into products, services and other technology-based
ventures. Arizona Technology Enterprises mines university research,
negotiates transactions, and markets inventions based on university
research. AzTE activities benefit the public by contributing to new
product creation and new economic opportunities. For more
information, visit www.azte.com.

Media Contacts:
TGen, Galen Perry (602) 343-8423
TGen, Amy Erickson (602) 343-8522
AzTE, Charlie Lewis (480) 965-8059

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Mayo Clinic Collaborative Research Building Opens on Scottsdale Campus

Mayo Clinic Collaborative Research Building Opens on Scottsdale
Campus

Collaboration with TGen brings hope for cancer cures

06-29-2005

SCOTTSDALE, Ariz. -- A major milestone in the advancement of cancer
research for residents of Arizona and beyond will be realized later
this week with the dedication of a new biomedical scientific
facility that joins Mayo Clinic and the Translational Genomics
Research Institute (TGen) in a unique strategic partnership. The
partners' combined technological, academic, research and clinical
expertise will help bring innovative research findings directly to
the bedside of patients.
The physical manifestation of this ambitious research collaboration
is the new Mayo Clinic Collaborative Research Building (MCCRB), a
110,000 square-foot facility that will officially open on Thursday,
June 30, on the Scottsdale campus of Mayo Clinic. The $25 million
facility was funded by Scottsdale developer Tom Hornaday of Hornaday
Development. The building is the first of its kind for Mayo Clinic
in that it brings multiple strategic partners under one roof
dedicated to scientific discovery and therapeutics to ease the
burden of disease for the people of Arizona and around the world.

Ground was broken in February 2004 for the MCCRB, which is located
south of the main clinic facility and directly north of the S.C.
Johnson Research Building. The collaboration represents a broadening
of the scope of research between the Mayo Clinic and TGen extending
beyond it's initial focus on melanoma. Tenants of the building thus
far include:

Mayo Clinic research business offices
Mayo Clinic researchers, including investigational labs for
hematologic malignancies, multiple myeloma and pancreatic cancer
TGen's Cancer Drug Development Laboratory (CDDL) and the TGen
subsidiary, TGen Drug Development (TD2)
Jeffrey M. Trent, Ph.D., is president and scientific director of
TGen. Dr. Daniel Von Hoff, TGen executive vice president, is also
director for TGen's Translational Research Division and the director
of TD2. In addition to leading TGen's clinical enterprise, Von
Hoff's team is involved in translating basic genetic, molecular and
biochemical observations to create therapies for patients with
pancreatic cancer.

The CDDL provides a centralized set of resources for investigators
interested in the recent explosion in molecular medicine and
genomics-based diagnostics and treatment methods. The combination of
world-class researchers and the latest technologies create a highly
collaborative multidisciplinary research environment. The goal is to
develop innovative preclinical research products based on an
individual's disease and associated molecular profiles that are
brought to bear on cancer as quickly as possible.

Mayo Clinic, headed by Dr. Victor F. Trastek, chair of the Board of
Governors, has research investigators who work closely with
clinicians to translate discoveries into therapies for patients.
Specifically, their work supports the Mayo Clinic Cancer Center, one
of only 38 U.S. medical centers named a National Cancer Institute
(NCI)-designated Comprehensive Cancer Center. Mayo's clinical and
research experts join forces to address the complex needs of
oncology patients.

The principal collaborative partners who will be housed at the MCCRB
partners share a passion for cooperation among institutions and
individuals to bring advances to cancer research. But they also
share something more -- compelling personal stories reflective of
their commitment to cancer research.

Developer Hornaday and his wife, Ruth Ann, lost their daughter,
Kristi, 26, to melanoma. Hornaday's mother died at age 52 of breast
cancer. "My hope, my prayer and my belief is that the research
conducted in this building will result in cures so others will not
experience these kinds of untimely losses," notes Hornaday.

Speakers at the opening will include Trastek, Trent, Von Hoff and
Hornaday, as well as Scottsdale Mayor Mary Manross and Dr. Laurence
Miller, deputy director of the Mayo Clinic Cancer Center. Both Trent
and Von Hoff share Hornaday's passion for finding a cure. They
experienced the loss of a close friend and mentor when founding
Arizona Cancer Center director, Dr. Sydney Salmon, passed away in
2002.

Trastek is a thoracic surgeon who has witnessed more than his share
of cancer-related diseases. At one time in his practice he chaired a
committee of the Society of Thoracic Surgeons whose charge was a
high-profile public campaign to encourage smoking cessation.

"Pursuing joint research strategies and building strong partnerships
with researchers at TGen helps advance Mayo Clinic's mission of
integrating research and education with clinical medicine to provide
optimal health care for our patients and patients everywhere," said
Trastek.

"The TGen-Mayo Clinic collaboration signifies a milestone, both in
terms of Arizona's leadership in bringing the best that biomedicine
has to offer to patients nationally and internationally and the
potential that research results between these two institutions will
have toward defeating cancer," said Sen. John McCain.

For Trent, it's the extension of a research vision that began with
TGen's formation in 2002.

"The collaboration signifies hope for those patients battling
cancer. All of us in this partnership understand their urgency, and
together we are committed to moving swiftly toward solutions that
will make a difference in our patients lives," said Trent.

About Mayo Clinic
Mayo Clinic is a charitable, not-for-profit organization with
locations in Arizona, Minnesota and Florida. For more than a
century, Mayo has been an international leader in patient care,
health sciences research and medical education. Since opening in
Scottsdale in 1987, Mayo has evolved into an integrated, multi-
campus system that includes the clinic, the Samuel C. Johnson
Research Building and the Mayo Clinic Collaborative Research Center
in Scottsdale, and Mayo Clinic Hospital in northeast Phoenix.

About TGen
The mission of the Translational Genomics Research Institute (TGen)
is to make and translate genomic discoveries into advances in human
health. Translational genomics research is a relatively new field
employing innovative advances arising from the Human Genome Project
and applying them to the development of diagnostics, prognostics and
therapies for cancer, neurological disorders, diabetes and other
complex diseases. TGen is focused on personalized medicine and plans
to accomplish its goals through robust and disease-focused research
programs and its state-of-the-art bioinformatics and computational
biology facilities.

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Tuesday, June 28, 2005

[ biotech news ] Research and Markets: Introducing a 29-Question Survey of More than 600 Life Sci

Research and Markets: Introducing a 29-Question Survey of More than
600 Life Scientists in North America

http://www.arizonabiotech.com/

Research and Markets
(http://www.researchandmarkets.com/reports/c19899) has announced the
addition of Information Technology in the Life Sciences: An
Examination of Genomics Researchers to their offering.

The bottleneck in many labs is data integration and analysis, and
poor data integration often leads to reduced productivity. Because
scientists are increasingly compiling data from multiple sources and
instrument platforms that were never intended to be compatible,
instrumentation suppliers and IT vendors are challenged to provide
solutions that integrate this data. These companies are also faced
with the challenges of disseminating this data to other institutions
as well as improving user interfaces to accommodate scientists with
little IT background. These IT challenges provide many market
opportunities. Instrument companies are developing new applications,
and independent software vendors are creating software that keeps up
with increased demands for better throughput and compatibility.
Finally, IT vendors are venturing into new markets. All of these
companies must keep up with the demands and needs of life scientists
in order to remain competitive.

Based on a 29-question survey of more than 600 life scientists in
North America, Information Technology in the Life Sciences: An
Examination of Genomics Researchers will help instrumentation
suppliers and IT vendors understand how academic and industrial
scientists use IT tools from start to finish in their genomics
experiments. It explores both researchers' use of, and satisfaction
with, various types of software and hardware. Additionally, the
report will assist companies in identifying future opportunities as
well as provide them with information that can be used to expand
their internal capacity by forming strategic alliances and
partnerships.

The major objectives of this report are as follows:

-- Measure the current usage patterns for the IT systems used in
genomics research.

-- Ascertain differences between researchers in the academic and
industrial market segments in their usage of genomics hardware and
software.

-- Evaluate levels of satisfaction with components of IT systems for
genomics research.

-- Determine future opportunities regarding high performance
computing, collaborative tools and storage area networks.

A preview of key findings derived from just a few of the survey
questions:

-- Applied Biosystems is the most frequently cited supplier of
fragment analysis/genotyping systems and real-time PCR instruments
used to generate genomics data. (Question 6)

-- Regardless of the instrument used to generate genomics data, more
than two-thirds of respondents analyze their data using software
embedded on it. (Question 7)

-- More than half of the scientists surveyed (59%) obtain software
used to analyze/integrate their data through a commercial third
party. (Question 9)

-- According to respondents, Dell and Apple are the leading
suppliers of desktop computer/workstation hardware used to study
genomics data. (Question 16)

-- Roughly one-third of respondents believe high performance
(distributed/grid/clusters) computing will be highly useful (a score
of 6 or 7 on a 7-point scale where 7=very useful) in their research
within the next 12 to 24 months. (Question 20)

-- Most respondents perceive IBM to be the best qualified provider
of collaborative software at their institutions. (Question 25)

http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Teva and Active Biotech Announce the Submission of an IND to the FDA

Teva and Active Biotech Announce the Submission of an IND to the FDA
for Laquinimod, an Oral Product for the Treatment of Relapsing MS

JERUSALEM & LUND, Sweden
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active
Biotech AB (Stockholm: ACTI.ST) announced today the submission of an
investigational new drug application (IND) to the U.S. Food and Drug
Administration (FDA) to initiate a clinical trial in the U.S. with
laquinimod to assess drug-drug interaction. Based on the results of
this study and of the ongoing phase IIb study in Europe (see below),
the phase III clinical program to confirm the efficacy and safety of
laquinimod in relapsing forms of MS, is planned to start in 2006.

Laquinimod is a novel orally administered immunomodulatory
substance, developed by Active Biotech and recently licensed to
Teva.

"I am pleased to report on this significant milestone," said Israel
Makov, President and CEO of Teva. "This IND filing is an important
step towards the initiation of pivotal studies with laquinimod
which, along with Teva's development of an oral form of Copaxone(R),
enhance the likelihood that Teva will be the first to market an oral
treatment. This further demonstrates our commitment to developing
new and improved therapies for multiple sclerosis patients in order
to help treat their disease and improve their quality of life".

"We are very pleased to see how Teva's development program is
diligently progressing towards starting phase III studies in the
U.S. and Europe," said Sven Andreasson, President & CEO of Active
Biotech. "Laquinimod has a profile that meets the need for a safe
and efficacious oral MS drug suitable for long term treatment."

Laquinimod has the potential to be the first orally-administered
disease modifying treatment for multiple sclerosis, both as a single
agent therapy and in combination with Copaxone(R), Teva's well-
established and leading product on the market today.

A double-blind, placebo-controlled multi center phase IIb clinical
study is currently on-going in several European countries, in which
the effects of laquinimod, administered orally, once-daily, at dose
levels of 0.3 and 0.6 mg/day, are compared to those of placebo over
9 months of treatment.

About laquinimod

Laquinimod is a novel immunomodulatory substance developed as an
orally bio-available disease modifying treatment of MS. Laquinimod
is the lead candidate drug identified from Active Biotech's SAIK
research program, in which the safety/activity ratio has been
optimized.

In a completed randomized, double-blind, placebo-controlled, multi-
center phase II trial, 209 patients received either laquinimod, at
dose levels of 0.1 or 0.3mg/day, or placebo, orally, once daily for
24 weeks. Laquinimod, at the dose of 0.3mg/day, reduced disease
activity (as measured by MRI) by 44%. In a sub-group of patients
with active MRI brain lesions prior to treatment initiation, the
same dose of laquinimod reduced disease activity by 52%. In this
study, laquinimod demonstrated a very favorable safety profile,
suitable for long-term treatment (Neurology 2005; vol 64, No. 6 p
987).

About Multiple Sclerosis (MS)

Multiple sclerosis (MS) is a chronic, progressive disease of the
central nervous system. It is the most common neurological disease
causing disability in young adults. It has been described as an
autoimmune disease because it is one of many diseases in which the
immune system attacks healthy areas of the body as if they were
foreign. In MS, these attacks are aimed at the central nervous
system. The central nervous system is made up of nerves covered by a
substance called myelin, which is similar to insulation protecting
electrical wires because it surrounds and protects nerve fibers.
When myelin or the nerve fiber is destroyed or damaged, the nerves
cannot send electrical impulses to and from the brain, causing the
onset of MS symptoms.

About Teva:

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is
among the top 20 pharmaceutical companies and among the largest
generic pharmaceutical companies in the world. The company develops,
manufactures and markets generic and innovative human
pharmaceuticals and active pharmaceutical ingredients. Close to 90%
of Teva's sales are in North America and Europe. Teva's innovative
R&D focuses on developing novel drugs for diseases of the central
nervous system.

About Active Biotech

Active Biotech AB is a biotechnology company focusing on research
and development of pharmaceuticals. Active Biotech has a strong R&D
portfolio with pipeline products focused on autoimmune/inflammatory
diseases and cancer. Its most advanced projects are laquinimod, an
orally administered small molecule with unique immunomodulatory
properties for the treatment of multiple sclerosis, as well as
ANYARA for use in cancer immunotherapy with the primary indication
non-small cell lung cancer. Further key projects in clinical
development comprise the three orally administered compounds TASQ
for prostate cancer 57-57 for SLE and RhuDex(R) for RA.

Safe Harbor Statement under the U. S. Private Securities Litigation
Reform Act of 1995: This release contains forward-looking
statements, which express the current beliefs and expectations of
management. Such statements are based on management's current
beliefs and expectations and involve a number of known and unknown
risks and uncertainties that could cause Teva's future results,
performance or achievements to differ significantly from the
results, performance or achievements expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include Teva's ability to
successfully develop and commercialize additional pharmaceutical
products, the introduction of competitive generic products, the
impact of competition from brand-name companies that sell or license
their own generic products (so called "authorized generics") or
successfully extend the exclusivity period of their branded
products, the effects of competition on Copaxone(R) sales, Teva's
ability to rapidly integrate the operations of acquired businesses,
including its acquisition of Sicor Inc., regulatory changes that may
prevent Teva from exploiting exclusivity periods, potential
liability for sales of generic products prior to completion of
appellate litigation, including that relating to Neurontin, the
impact of pharmaceutical industry regulation and pending legislation
that could affect the pharmaceutical industry, the difficulty of
predicting U.S. Food and Drug Administration, European Medicines
Association and other regulatory authority approvals, the regulatory
environment and changes in the health policies and structure of
various countries, Teva's ability to successfully identify,
consummate and integrate acquisitions, exposure to product liability
claims, dependence on patent and other protections for innovative
products, significant operations outside the United States that may
be adversely affected by terrorism or major hostilities,
fluctuations in currency, exchange and interest rates, operating
results and other factors that are discussed in Teva's Annual Report
on Form 20-F and its other filings with the U.S. Securities and
Exchange Commission. Forward-looking statements speak only as of the
date on which they are made and the Company undertakes no obligation
to update publicly or revise any forward-looking statement, whether
as a result of new information, future developments or otherwise.

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Rosetta Genomics Identifies Hundreds of Novel Human microRNAs, Study Published i

Rosetta Genomics Identifies Hundreds of Novel Human microRNAs, Study
Published in Nature Genetics Shows

- Novel approach identifies 89 novel new human microRNAs, nearly
doubling the number of human microRNAs sequenced to date, and
predicts number exceeds 800.
- First report of large number of primate specific microRNA,
postulated to play an important role in differentiation and
evolution.

REHOVOT, Israel, In a study published online this week and to be
published as a cover story in the July issue of Nature Genetics,
Rosetta Genomics' scientists report identification of hundreds of
human microRNA genes, including the first report of primate specific
microRNAs. Using a novel methodology, the researchers successfully
cloned and sequenced 89 human microRNAs, nearly doubling the number
sequenced in man to date.
MicroRNAs are a recently discovered class of tiny regulatory genes,
comprised in the 98% of the genome that does not encode proteins,
which until recently were considered 'Junk DNA'. Numerous recent
studies have shown microRNA genes, far from being 'junk', are in
fact of central importance, regulating at least 30% of all proteins,
and involved in a wide range of diseases, including diabetes,
obesity, viral diseases, and various types of cancer.

"The finding of large numbers of primate specific microRNAs is
exciting because it supports the notion that microRNAs may indeed
play an important role in the evolution of complexity of higher
organisms," said Aaron Ciechanover, Nobel prize laureate 2004, and
Chairman of Rosetta Genomics' Scientific Advisory Board. "We believe
that these genes may serve as an important basis for next generation
diagnostics and therapeutics."

"We are extremely pleased to report our success in nearly doubling
the number of human microRNAs sequenced to date, results which we
believe establish Rosetta Genomics as a leading player in discovery
of microRNA genes," said Isaac Bentwich MD, founder and chairman of
Rosetta Genomics and lead investigator of the study. "We are now
aggressively pursuing partnerships for development of diagnostics
and therapeutics based on this huge group of novel microRNAs."

About microRNAs

MicroRNAs are a recently discovered group of non-protein-coding
regulatory genes, shown to be involved in a wide range of diseases
in addition to neuronal and stem-cell differentiation. MicroRNAs
currently are an intensely researched area, and are believed
potentially to be the basis for a new class of therapeutic and
diagnostic products.

About Rosetta Genomics

Rosetta Genomics is a privately held genomics company, pioneering
the discovery and commercialization of microRNAs - a novel group of
regulatory genes, shown to be involved in a wide range of diseases
including diabetes, obesity and various types of cancer. Rosetta has
discovered and filed patents for the majority of microRNAs found to
date, and is in the process of developing diagnostics and
therapeutics based on these microRNAs, by both internal development
and collaborative partnerships.

Rachel Spielman Sharon Kaspi
Ruder Finn Rosetta Genomics Media Relations
Tel +1 212 583 2714 Tel +1 201 255 5900
Mobile +1 646 872 2985 Mobile +1 201 255 5914
spielmanr@ruderfinn.com sharon@rosettagenomics.com

---------------------------------------------------------------------
-----------
Source: Rosetta Genomics

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Galapagos and Celera Genomics Sign Gene Function Analysis Agreement

Galapagos and Celera Genomics Sign Gene Function Analysis Agreement

ROCKVILLE, M.D. and MECHELEN, Belgium, June 20, 2005
Galapagos today announced that it has entered into a services
agreement with Celera Genomics Group (NYSE:CRA), an Applera
Corporation business. Under the agreement, Galapagos' services
division Galadeno will provide technology and adenoviral reagents
enabling Celera to analyze gene function in human cells and validate
potential drug targets. Galadeno will receive payments related to
its services and technology.Under the terms of the agreement,
Galadeno will construct recombinant adenoviruses harboring genes
selected by Celera. These custom-made viruses will be used to
introduce the genes into various cell types to evaluate their
function within biological pathways.

"We are delighted that Celera has decided to take advantage of
Galapagos' adenoviral technology. This service agreement will allow
Celera to utilize Galapagos' technology platform to perform cellular
assays and target validation studies in a very beneficial way," says
Onno van de Stolpe, CEO of Galapagos. "Our adenoviral platforms have
proven to deliver functionally validated drug targets for our
partners, opening significant opportunities for continued
collaboration. We are pleased that Celera has joined the growing
number of companies that choose Galapagos technology to study gene
function in human cells."

About Celera Genomics and Applera Corporation Applera Corporation
consists of two operating groups. The Celera Genomics Group is
engaged principally in the discovery and development of targeted
therapeutics for cancer, autoimmune and inflammatory diseases.
Celera Genomics is leveraging its proteomic, bioinformatic, and
genomic capabilities to identify and validate drug targets, and to
discover and develop small molecule therapeutics. It is also seeking
to advance therapeutic antibody and selected small molecule drug
programs in collaboration with global technology and market leaders.
The Applied Biosystems Group (NYSE:ABI) serves the life science
industry and research community by developing and marketing
instrument-based systems, consumables, software, and services.
Customers use these tools to analyze nucleic acids (DNA and RNA),
small molecules, and proteins to make scientific discoveries,
develop new pharmaceuticals, and conduct standardized testing.
Applied Biosystems is headquartered in Foster City, CA, and reported
sales of $1.7 billion during fiscal 2004. Celera Diagnostics, a
50/50 joint venture between Applied Biosystems and Celera Genomics,
is focused on discovery, development, and commercialization of
diagnostic products. Information about Applera Corporation,
including reports and other information filed by the company with
the Securities and Exchange Commission, is available at
www.applera.com, or by telephoning +1.800.762.6923. Information
about Celera Genomics is available at www.celera.com.

About Galapagos

Galapagos is a publicly traded, genomics-based drug discovery
company (Euronext Brussels, GLPG; Euronext Amsterdam, GLPGA) that
has successfully discovered and validated novel targets in the bone
and joint diseases - osteoarthritis, osteoporosis and rheumatoid
arthritis, as well as in asthma and Alzheimer's disease. Proprietary
targets and compounds resulting from these programs are used for
Galapagos' internal drug discovery programs, combined with selected
out-licensing and partnering of projects during development.
Galadeno, Galapagos' services unit, provides reagents and functional
screens to leading pharmaceutical, biotech and nutraceutical
companies for rapid identification and validation of novel drug
targets. Galapagos currently employs 69 people, including 17 PhDs,
and occupies facilities in Mechelen, Belgium, and Leiden, The
Netherlands. Partners include Bayer, Boehringer Ingelheim, Celgene,
GlaxoSmithKline, Vertex and Wyeth.

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Monday, June 27, 2005

Biomarker Alliance 'TM' to be sponsored by MDS Pharma Services

Biomarker Alliance 'TM' to be sponsored by MDS Pharma Services

MDS Pharma Services Sponsors The Biomarker Alliance'TM'

Biomarker Alliance integrates world-class biomarker service providers Caprion Pharmaceuticals, Gentris Corporation, Massachusetts General Hospital Department of Radiology and MDS Pharma Services

MDS Pharma Services, a leading provider of innovative drug discovery and development solutions, has spearheaded the formation of The Biomarker Alliance(TM) (www.biomarkeralliance.com) serving the pharmaceutical and biotechnology industries. The Biomarker Alliance, which will design and execute a wide range of biomarker discovery and development programs, is made up of the world-class biomarker service providers Caprion Pharmaceuticals, Gentris Corporation, Massachusetts General Hospital Department of Radiology and MDS Pharma Services.

"The Biomarker Alliance is on the crest of that wave with its collective insight, expertise and seamless program management. These capabilities enable the Biomarker Alliance to significantly reduce drug discovery and development timelines while eliminating the need to invest in multiple technology platforms and infrastructure," says Dr. J. Fred Pritchard, vice president, Drug Development Programs, MDS Pharma Services.

"The economics and uncertainties of drug development demand that successful companies quickly demonstrate the safety and efficacy of their compounds," says Lloyd M. Segal, president and CEO, Caprion Pharmaceuticals. "Using biomarkers to make key development decisions early can reduce development timelines and increase the likelihood of regulatory and clinical success, thereby maximizing market positioning."

"MDS Pharma Services' sponsorship of The Biomarker Alliance is quite logical since we have a long and successful biomarker history, and we have the world's largest array of validated biomarker assays," says Pritchard.

The Biomarker Alliance is unique. It is the only organization providing single-point access to proteomics, pharmacogenomics, imaging, assay development and clinical testing together in one, easy-to-access package designed to maximize the probability of success of any drug candidate.

"This combination of services is ideal since it represents the type of work in which our clients are already expressing interest," says Michael Murphy, president and CEO, Gentris Corporation.

"The members of the Alliance have seen the future and the potential. They know what it will take to identify and apply biomarkers in a scientific manner that expresses the safety and efficacy of new compounds that could potentially change the way medicine is practiced today," says Murphy.

In addition to the seamless program-management services offered by MDS Pharma Services, the Alliance's clients' have access to:

Caprion Pharmaceuticals, Montreal, Canada (www.caprion.com) --- the pharmaceutical industry partner of choice for protein biomarker discovery;

Gentris Corporation, Research Triangle Park, N.C. (www.gentris.com) --- the leading global provider of applied clinical pharmacogenomic services and products;

Massachusetts General Hospital Department of Radiology, Boston, Mass. (www.massgeneralimaging.org) --- a pioneering leader in imaging biomarkers and the use of imaging technology in clinical trials; and

MDS Pharma Services, King of Prussia, Pa. (www.mdsps.com) --- the premier provider of biomarker discovery, development and implementation.

"Biomarkers are becoming more critical in the process of discovering and developing new drugs and in determining additional uses for established drugs. Biomarkers are ushering in the age of personalized medicine," notes Pritchard.

(1) CONTRACT PHARMA May 2005

About MDS Pharma Services

MDS Pharma Services offers a full spectrum of resources to meet the drug discovery and development needs of the pharmaceutical and biotechnology industries. With numerous facilities strategically located around the world, the company applies advanced scientific and technological expertise to each stage of the drug discovery and development process - Early Stage: lead optimization, pre-IND research, pharmaceutical and biopharmaceutical development, early clinical research (bioequivalence, Phases I-IIa) and bioanalysis; and Late Stage: global clinical development (Phases IIb-IV) and central lab. For more information, visit MDS Pharma Services' Web site at www.mdsps.com.

MDS Pharma Services is an integral part of MDS Inc. (TSX: MDS; NYSE: MDZ). MDS Inc. has more than 9,000 highly skilled people in 27 countries. MDS Inc. provides a diverse range of superior products and services to increase its customers' speed, precision and productivity in the drug development and disease diagnosis processes. MDS Inc. is a global, values-driven health and life sciences company, recognized for its reliability and collaborative relationships as it helps create better outcomes in the treatment of disease. For more information, visit MDS Inc.'s Web site at www.mdsintl.com.

About Caprion Pharmaceuticals

Caprion is a leading proteomics-based drug discovery company applying CellCarta(R) to discover and develop innovative products for the diagnosis and treatment of disease. Caprion has established therapeutic antibody discovery partnerships with Abbott Laboratories in Lung Cancer, and Biogen IDEC (NASDAQ: BIIB) in Colon Cancer, and pharmaco-proteomic discovery collaborations with Wyeth (NYSE: WYE), AstraZeneca (NYSE: AZN), Merck & Co (NYSE: MRK), and Pfizer (NYSE: PFE). Caprion's partners also include IDEXX Laboratories (NASDAQ: IDXX) and Ortho-Clinical Diagnostics (NYSE:JNJ). Caprion's therapeutic antibodies for the prevention of Hemolytic Uremic Syndrome (HUS) resulting from E. coli infection are currently in Phase I clinical trials. For more information, visit Caprion's Web site at www.caprion.com.

About Gentris Corporation

Gentris Corporation is a leading global provider of applied clinical pharmacogenomic services and diagnostic product solutions. As pioneers in the field of pharmacogenomics, Gentris helps pharmaceutical companies and clinical research organizations effectively integrate pharmacogenomics into their drug development programs to deliver safer, more effective compounds to the market sooner. Gentris is developing diagnostic test kits and validated reference controls that will bring the promise of personalized medicine to physicians and patients, which will enhance patient management, improve patients' response to therapy and revolutionize medicine through pharmacogenomics. For more information, visit Gentris's Web site at www.gentris.com.

About Massachusetts General Hospital Department of Radiology

The Massachusetts General Hospital Department of Radiology is an academic, non-profit organization and a major teaching affiliate of Harvard Medical School. A true pioneer in the realm of medical imaging, Mass General relies on its renowned subspecialty expertise and clinical trials experience to offer a vast array of imaging services, including: project management, protocol and study planning, development of image acquisition and analysis guidelines, and qualitative & quantitative surrogate endpoint image analysis for Phase I-IV trials. The MGH Center for Biomarkers in Imaging draws on MGH Radiology's extensive experience in working with industry, academia and the government and is dedicated to the identification, characterization and validation of image-related biomarkers. For more information, visit MGH's Web site at www.massgeneralimaging.org or www.biomarkers.org.

Biotech News 0 comments

Arizona Biotech

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Genome study of beneficial microbe may help boost plant health

Genome study of beneficial microbe may help boost plant health

ROCKVILLE, Md - In a study expected to greatly benefit crop plants,
scientists have deciphered the genome of a root- and seed-dwelling
bacterium that protects plants from diseases.

The research provides clues to better explain how the helpful
microbe, Pseudomonas fluorescens Pf-5, naturally safeguards roots
and seeds from infection by harmful microbes that cause plant
diseases. The genome paper will be published in Nature Biotechnology
and was scheduled to be posted online on June 26.

"The genome sequence has helped us identify new chemical pathways
that the microbe apparently uses to create what are known
as 'secondary metabolites' possibly including new antibiotic
compounds," says Ian Paulsen. He led the sequencing at The Institute
for Genomic Research (TIGR), Rockville, Md., and is the study's
first author.

The use of naturally-occurring, beneficial microbes such as P.
fluorescens to control plant pathogens is called "biological
control." That method is gaining momentum as a way to grow healthy
plants without using synthetic fungicides. In all, about three dozen
beneficial microbes are currently used as an environmentally-
friendly way to fight plant diseases.

Joyce E. Loper, senior author of the genome paper and an expert on
P. fluorescens Pf-5, predicts that the new genomic data will help
scientists more quickly develop new ways to boost the effectiveness
of beneficial microbes in fighting plant diseases.

"This genomic sequence reveals previously unknown traits of P.
fluorescens that increase its potential for biological control,"
says Loper. She is a plant pathologist with USDA's Agricultural
Research Service (ARS) and is based at Oregon State University,
Corvallis. The P. fluorescens genome was sequenced at TIGR and
analyzed by scientists there and at ARS and Oregon State University,
with contributions by researchers at Rutgers, Washington State
University and the University of Arizona. The project was funded by
a grant from the USDA's Cooperative State Research, Education and
Extension Service.

The article in Nature Biotechnology presents the first complete
genome sequence of a biological control agent for combating plant
diseases.

P. fluorescens Pf-5 was discovered two decades ago by Charles R.
Howell, a plant pathologist with the ARS in Texas, who showed that
the microbe suppressed two major cotton diseases. Since then, plant
pathologists around the world have used this strain as a laboratory
model to study beneficial microbes.

Paulsen says the P. fluorescens project also pioneered a new
methodology. This novel approach relies on the analysis of repeated
regions of the DNA sequence to help identify segments of the genome
that appear to have been transferred from other microbes or viruses,
known as phages, that infect bacteria.

Says Paulsen: "We found exciting evidence that P. fluorescens may
have acquired new clusters of genes, called genomic islands, by
means of lateral transfer from phages or other microbes."

###
The Institute for Genomic Research (TIGR) is a not-for-profit
research institute based in Rockville, Maryland. TIGR, which
sequenced the first complete genome of a free-living organism in
1995, has been at the forefront of the genomic revolution since the
institute was founded in 1992. TIGR conducts research involving the
structural, functional, and comparative analysis of genomes and gene
products in viruses, bacteria, archaea, and eukaryotes.

As the principal in-house research arm of the U.S. Department of
Agriculture, the Agricultural Research Service (ARS) conducts
research to develop and transfer solutions to agricultural problems
of high national priority and provides information access and
dissemination to ensure high-quality, safe food and other
agricultural products, assess the nutritional needs of Americans,
sustain a competitive agricultural economy, enhance the natural
resource base and the environment, and provide economic
opportunities for rural citizens, communities, and society as a
whole.

Oregon State University is known nationally and internationally for
the quality of its academic programs, its research excellence and
its service and outreach. OSU is one of only two universities in the
nation that are designated land grant, sea grant, space grant and
sun grant institutions.

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech
News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona
Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Biotechnology Forums: http://www.arizonabiotech.com/index.php

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Saturday, June 25, 2005

[ biotech news ] BIO 2006

BIO 2006

http://www.bio.org/events/2006/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

BIO 2006

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Biotech Question of the Week: Got Space?

Biotech Question of the Week: Got Space?

Postcard Campaign Seeking to Find Lab Space for Startups
By MARION WEBB

San Diego Business Journal Staff

Hundreds of San Diego-based biotechnologies will receive postcards
this week with an unusual proposition: Got space?

The Burnham Life Sciences Group, a specialty arm of San Diego-based
Burnham Real Estate, will drop some 700 postcards in the mail
encouraging local companies to lease access or temporary laboratory
space to fledgling companies having a tough time getting started.

"The space requirements for young biotech companies are challenging
in that they need facilities that can accommodate their research,
but generally at a size that is too small to be listed," said Brent
Jacobs, senior vice president of Burnham's Life Sciences Group. "Of
the 15 million square feet of lab space in San Diego County, nearly
all of the available space is 10,000 square feet or larger far
more than the 1,000 to 3,000 square feet of wet lab space typically
required by startup companies."

Greg Bisconti, a partner with Burnham's Life Sciences Group, said
few landlords are willing to sign month-to-month, six-month or 12-
month leases that startups on tight budgets and risky scientific
projects can afford to sign.

http://www.sdbj.com/article.asp?aID=`162971.2745761.1160926.8983597.86472502.120&aID2=293

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Asian `biotech hotbeds' must develop USP: E&Y report

Asian `biotech hotbeds' must develop USP: E&Y report
P.T. Jyothi Datta

Mumbai , June 25

IT may still puzzle analysts why biotechnology is trusted when used
in medicine, but viewed with suspicion when used in agriculture. But
be it medicine or agriculture, Japan, China and India are the
emerging "biotech hotbeds," says an Ernst and Young (E&Y) report,
released recently at Bio 2005 in Philadelphia.

Nevertheless, "each country has to have its USP (unique selling
proposition), otherwise me-too products will be developed. And the
USP has to be matched with the bio-diversity of each country," says
E&Y's Mr Utkarsh Palnitkar, who presented the report at Bio 2005.

India's strengths are in processing, fermentation, informatics and
its vaccine manufacturing capacity. By 2010, the country will be the
largest manufacturer of vaccines in the world, Mr Palniktar told
Business Line. Also, in terms of the neglected diseases seen in
Africa, South-America and India it makes sense to research
diseases in India, he said.

China's strengths are in bio-processing, and Korea has made strides
in stem-cell research.

In Korea, the legislation has moved in tandem with therapeutic
cloning and, as a result, companies such as LG and Samsung have
become large filers of patents, said Mr Palnitkar.

Singapore has the regulatory environment and infrastructure in
place, but it has to look outwards for people to man these, he said.

The support of the governments in India, Singapore, China and Korea,
in terms of infrastructure and policy, has given an impetus to the
biotech segment in these regions, said Mr Palnitkar, Health Sciences
leader with E&Y in India.

http://www.thehindubusinessline.com/2005/06/26/stories/2005062601390500.htm

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Friday, June 24, 2005

[ biotech news ] UCLA awarded more than $6 million for biodefense and infectious disease researc

UCLA awarded more than $6 million for biodefense and infectious
disease research

UCLA has been awarded more than $6 million over four years by the
National Institute of Allergy and Infectious Diseases to support
research for countering threats from bioterrorism agents and
infectious diseases. UCLA will be a major component of the Pacific?
Southwest Center for Biodefense and Emerging Infectious Diseases
Research, a consortium of more than a dozen universities and
research institutes in California, Arizona, Nevada and Hawaii.

"Our hope is to increase fundamental knowledge on bacterial and
viral pathogens and help mitigate the bioterrorism threat," said
Jeffery F. Miller, professor and chair of microbiology, immunology
and molecular genetics at UCLA, and the center's associate director
for basic research.

Miller's laboratory will focus on bacterial pathogens and will study
an environmental organism that causes pneumonia and septicemia, and
is a potential bioterror threat. Numerous safety precautions will be
in effect, as required under federal regulations. The researchers
will work with the organism under tightly controlled conditions,
with high security and extensive oversight by the university and
federal agencies.

"This bacterium has a large genome and is largely unexplored," said
Miller, who holds UCLA's M. Philip Davis Chair in Microbiology and
Immunology. "We will work to learn the fundamental mechanisms of its
cell biology and how it causes disease. It enters cells and injects
proteins into cells using a molecular syringe."

"Our center will bring together some of the country's best basic
scientists and engineers for the common goal of preventing illness
by developing more accurate tests to detect infections and new
vaccines to protect people," said Alan Barbour, professor of
medicine and microbiology at the University of California, Irvine,
who will serve as director of the new center. Barbour is
internationally known as a co-discoverer of the bacterium that
causes Lyme disease; he also identified the protein that became an
approved vaccine against the disease.

While the center's goals include scientific applications to detect,
prevent and treat diseases and bio-agents -- including developing
vaccines -- Miller and Barbour also emphasized the importance of
basic scientific research in providing the foundation for creating a
defense against diseases and potential bioterrorism agents.

"Basic research is essential, and provides a foundation for future
applications," said Miller, a member of both UCLA's David Geffen
School of Medicine and the UCLA College. "We will study the
fundamental mechanisms of how bacterial pathogens work and cause
disease."

Miller noted that the discovery of restriction enzymes, a
fundamental tool for pharmaceutical and biotechnology companies, was
the result of pure intellectual curiosity.

"Restriction enzymes were discovered years ago not by biochemists or
geneticists looking for something practical, but because a bacterial
virus would infect one strain of E. coli, but not another; the
strain the virus would not infect expressed these enzymes that would
chop apart the bacterial virus' DNA. The researchers who made this
discovery had no immediate practical applications in mind, and yet
what came from that discovery is an indispensable tool in the
pharmaceutical and biotechnology industry.

"In addition, knowledge of the genomes of bacterial pathogens
required many years of research on model organisms such as E. coli,"
he added. "There are many such examples of the essential role basic
science has played in leading to essential medical applications."

Overall, the National Institute of Allergy and Infectious Diseases
has awarded $40 million over four years to establish the Pacific?
Southwest Center for Biodefense and Emerging Infectious Diseases
Research, which will be based at the University of California,
Irvine. The institute is part of the National Institutes of Health.

The center is one of only 10 federally funded regional centers
dedicated to research for countering threats from bioterrorism
agents and infectious diseases. Its mission will be to bolster basic
biomedical research into bioterrorism agents, such as those that
cause anthrax and botulism, and naturally occurring infectious
diseases, including West Nile virus, hantavirus and dengue, which
affect increasing numbers of people worldwide. It also will provide
scientific support, expertise and facilities in response to a
national emergency, such as a terrorist attack or an epidemic of a
new infectious disease, like the SARS virus.

The center also will create a clinical trials unit for evaluating
new vaccines. In addition, the center will support a detailed
analysis of proteins and DNA that are key to understanding
infectious diseases and bioterrorism agents, and lead efforts to
apply recent computer and engineering advances toward improving
infection detection as well as outbreak management.

In addition to Miller, researchers at UCLA who will receive funding
from the institute are Marcus Horwitz, professor of medicine and
microbiology, immunology and molecular genetics; Yong Chen,
professor of mechanical and aerospace engineering; Adrian Casillas,
assistant professor of medicine; Joel Ward, professor of pediatrics
at the Harbor-UCLA Medical Center; Hartmuth Kolb, associate
professor of molecular and medical pharmacology; and Ronald Stevens,
professor of microbiology, immunology and molecular genetics.

The center also will consist of researchers from the University of
California, Irvine; the University of California, Davis; the
University of California, Berkeley; the University of California,
Santa Barbara; the University of Southern California; the California
Institute of Technology; the Scripps Research Institute in La Jolla;
the University of Hawaii; Stanford University; Northern Arizona
University; the University of Arizona; the Desert Research Institute
in Nevada; the California Department of Health Services; and
Lawrence Livermore National Laboratory. The center will sponsor 30
research projects involving 130 researchers, post-docs, students,
and technical and support staff.

The other Regional Centers of Excellence for Biodefense and Emerging
Infectious Diseases are based in the states of Colorado, Washington,
Texas, New York, Massachusetts, Illinois, Missouri, Maryland and
North Carolina.

For more information about the Regional Centers of Excellence for
Biodefense and Emerging Infectious Diseases research, see
niaid.nih.gov/Biodefense/Research/rce.htm.

Contact: Stuart Wolpert
stuartw@college.ucla.edu
310-206-0511
University of California - Los Angeles
www.healthcare.ucla.edu/news

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Osiris Raises $50 Million to Commercialize First Stem Cell Products; Proceeds wi

Osiris Raises $50 Million to Commercialize First Stem Cell Products;
Proceeds will advance three promising treatments currently in human
trials

Osiris Therapeutics, Inc. announces that it has finalized a $50
million aggregate private investment round through equity and
convertible debt. The financing will fund the company's three
ongoing clinical trial programs using their proprietary adult stem
cell technology platform. The round was arranged by Swiss investment
firm Friedli Corporate Finance, Inc.

"With this successful funding round and the progress being made in
the three clinical trials, Osiris continues to demonstrate its
ability to execute its commercialization plan," said Chairman of the
Board, Peter Friedli. Mr. Friedli is one of the founders of Osiris
and was instrumental in arranging the current financing.

"This level of support signifies the confidence our investors have
in Osiris to be the first company to bring a stem cell therapy to
market," said C. Randal Mills, PhD, President and CEO of Osiris. "As
always, we are pleased with the unwavering support of our loyal
investors, and we welcome the new investors who participated in the
round. The proceeds will be used to aggressively advance our product
commercialization plans and bring these revolutionary treatments to
patients in need."

The first product, Prochymal(TM), now in Phase II clinical trials,
is a formulation of adult stem cells to treat Graft versus Host
Disease (GvHD), a life threatening disease afflicting leukemia
patients who have received a bone marrow transplant. Osiris has
recently enrolled several prominent cancer centers in the trial
including the M.D. Anderson Cancer Center in Houston, Texas, one of
the world's leading bone marrow transplant facilities. "We are
hopeful that this therapy may be a viable treatment option for
patients suffering from this direct complication of
transplantation," said Partow Kebriaei, MD, Assistant Professor,
Blood and Marrow Transplantation at M.D. Anderson. "The treatments
available to us currently for Gastrointestinal GvHD are marginally
effective at best, which makes Prochymal a potentially significant
breakthrough."

The second product, Provacel(TM), a formulation of stem cells to
repair damaged heart tissue following heart attack, is enrolling
patients in a Phase I clinical trial. In preclinical studies,
Provacel reversed the damage caused by a heart attack and
significantly improved cardiac function. "This is a landmark study
that could ultimately benefit hundreds of thousands of patients a
year" said Nabil Dib, MD, Chief of Cardiovascular Research at the
Arizona Heart Institute. "The aim is to develop a stem cell product
that will repair the damage caused by a heart attack and prevent the
progression to heart failure."

Most recently, Osiris won approval from FDA to begin a Phase I/II
study for its third product, Chondrogen(TM), an injection of stem
cells formulated to repair damaged tissue in the knee joint and
prevent the progression of arthritis. Chondrogen, in development at
Osiris since 1999, has shown encouraging preclinical results that
served as the basis for FDA's decision. "The product has undergone
rigorous preclinical testing over the past six years and has shown
the ability to regrow functional meniscal tissue in as little as six
weeks," said C. Thomas Vangsness Jr., MD, Professor of Orthopedic
Surgery and Chief of Sports Medicine at the University of Southern
California's Keck School of Medicine. "More importantly, the product
prevented the progression of osteoarthritis in the knee."

Further portions of the proceeds will fund the continued enrichment
of the company's product pipeline and expand the company's extensive
intellectual property portfolio. The company currently holds more
than one hundred issued domestic and foreign patents, with over a
hundred more in various stages of approval. "Maintaining our current
patent portfolio and seeing our applications through to patent
grants will further solidify our already dominant intellectual
property position," said Cary J. Claiborne, Osiris' CFO. "This will
be especially critical as we begin to commercialize our stem cell
products and assert our considerable intellectual property rights."

About Osiris Therapeutics

Osiris Therapeutics, Inc. is the leader in adult stem cell therapy.
The stem cells produced by Osiris are obtained from adult volunteer
donors, avoiding the technical problems and controversy surrounding
other stem cell technologies. Using proprietary methods, these cells
are grown in culture to very high numbers, allowing a single donor's
cells to treat thousands of patients. These cells are universal in
that they can be used in patients unrelated to the donor, without
rejection, eliminating the need for donor matching and recipient
immune suppression. Once transplanted, the cells promote healing of
damaged or diseased tissues.

About Friedli Corporate Finance

Friedli Corporate Finance was founded by Peter Friedli in 1986 and
is one of the leading Swiss venture capital firms. Since its
inception, Friedli Corporate Finance has invested in over 170
biotechnology and technology companies, primarily based in the US.
Friedli Corporate Finance manages several investment companies for
pension funds, banks and large corporations in Switzerland. Peter
Friedli is also the manager of New Venturetec, a public investment
company listed on the Swiss exchange. www.newventuretec.com

For information about Osiris and our ongoing clinical trials, visit
our website at www.OsirisTx.com.

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] TGen Awarded $7.1 Million to Accelerate Brain Disease Research

TGen Awarded $7.1 Million to Accelerate Brain Disease Research

10,000 investigators now have access to the latest genetic scanning
technologies

June 17, 2005

The Translational Genomics Research Institute (TGen) today announced
the receipt of a $7.1 million grant from the National Institutes of
Health (NIH) to continue a project designed to uncover the genetic
causes of neurological and mental health disorders using
sophisticated genetic scanning technologies. This award is part of a
greater $25 million grant that TGen will share with three other
microarray centers that are part of the NIH Neuroscience Microarray
Consortium supported by the NIH Neuroscience Blueprint
(neuroscienceblueprint.nih.gov).
The Microarray Consortium was initially funded in 2002 by the
National Institute of Neurological Disorders and Stroke (NINDS;
www.ninds.nih.gov) and the National Institute of Mental Health
(NIMH; www.nimh.nih.gov). The new award is supported by these two
institutes as well as the thirteen other NIH Neuroscience Blueprint
institutes. The consortium combines technology resources from TGen,
Duke University in Durham, NC, and the University of California in
Los Angeles. Because of the consortium's success and an expanding
need for consortium services in neuroscience, a fourth research
center, Yale University in New Haven, Connecticut, will be added to
the program in June.

About 10,000 investigators from the 15 different NIH institutes that
are part of the NIH Neuroscience Blueprint will have access to the
technology and expertise within the consortium. These investigators
will be able to further their research through the use of microarray
technology used for scanning through the entire human genome (3
billion letters) and all of the genes for which it encodes (30,000-
40,000 genes).

"The application of the newest and most sophisticated genome
scanning technologies will allow us to unlock the mysteries of how
the brain functions normally, as well as what causes common human
disorders like Alzheimer's disease, multiple sclerosis, and others,"
said Dr. Dietrich A. Stephan, Director of the Neurogenomics Division
at the Translational Genomics Research Institute.

Genomic scanning technologies make use of the human genome sequence
to visualize how gene flavors or aberrant amounts of genes can cause
human disease. The consortium centers specialize in technologies
which provide information about the genes turned on or off in the
diseased tissues being studied. Scientists use these microarray
technologies to compare genetic patterns between an individual with
a disease and an unaffected person. Using this information,
investigators can identify the root causes responsible for certain
disorders so that diagnostics and treatments can be developed that
have a direct impact on the disease mechanisms.

The Microarray Consortium initially received $9 million from the NIH
from June 2002 to June 2005, and the new funding will be
approximately $25 million over the next five years.

"It is exciting to have the microarray consortium expanded in
capacity and expertise to serve the entire community of
neuroscientists funded by NIH institutes. The application of genomic
technologies in neuroscience is an important step in the development
of future therapies for diseases and disorders of the nervous
system," said Dr. Thomas Miller, Program Director of Extramural
Research Programs at the NINDS.

The consortium worked with 5 AM solutions, a software development
company in Phoenix, to create a central database for data generated
by the consortium. These data are freely available so the entire
scientific community can benefit from this publicly funded endeavor.

The Neuroscience Blueprint institutes are components of the National
Institutes of Health in Bethesda, Maryland and are the nation's
primary supporters of basic and applied biomedical research on the
brain and nervous system. Additional information about the NIH
Neuroscience Microarray Consortium can be accessed at
arrayconsortium.tgen.org.

# # #

About TGen The mission of the Translational Genomics Research
Institute (TGen) is to make and translate genomic discoveries into
advances in human health. Translational genomics research is a
relatively new field employing innovative advances arising from the
Human Genome Project and applying them to the development of
diagnostics, prognostics and therapies for cancer, neurological
disorders, diabetes and other complex diseases. TGen is focused on
personalized medicine and plans to accomplish its goals through
robust and disease-focused research programs and its state-of-the-
art bioinformatics and computational biology facilities.

About Duke The consortium's site at Duke University will operate in
concert with the Institute for Genome Sciences and Policy (IGSP).
The IGSP, established in 2000 with $200 million in institutional
funds, represents Duke University's comprehensive response to the
broad challenges of the genomic revolution. IGSP activities are
organized through five research centers: the Center for Genome
Technology, the Center for Human Genetics, the Center for Human
Disease Models, the Center for Bioinformatics and Computational
Biology and the Center for Genome Ethics, Law and Policy.

Arizona High Tech

Thursday, June 23, 2005

[ biotech news ] Generex Biotechnology Begins Research Collaboration on Novel Allergy Therapy Wit

Generex Biotechnology Begins Research Collaboration on Novel Allergy
Therapy With Major European Company

Stallergenes, a Principal European Allergy Firm Near Paris, Tests
Novel Approach to Immunotherapy of Allergy and Asthma Designed by
Antigen Express

Generex Biotechnology Corporation (Nasdaq: GNBT - News) today
announced that a Research Collaboration Agreement has been signed by
its subsidiary Antigen Express, Inc. with Stallergenes, S.A. a major
European firm in immunological treatments for allergy and asthma.

The studies are to design and test Ii-Key/allergen epitope hybrid
peptides to create a novel approach for the control of both
dangerous forms of asthma and functionally disabling allergic
reactions. A large number of individuals in both North America and
Europe suffer from various forms of allergic responses. These range
from allergic rhinitis to cat dander, to ragweed hayfever, to
potentially fatal asthmatic attacks from bee sting or peanut
allergens.

Antigen Express scientists have discovered that a segment of the
immunoregulatory protein called Ii, acts on the HLA-DR molecules,
which present antigenic peptide epitopes of allergens to T
regulatory lymphocytes. By coupling this Ii-Key peptide covalently
to the antigenic epitope peptides, the potency of the HLA-DR
presented epitope is increased about 200 times in cell culture
experiments and about 8 to 10 times after injecting animals.

Allergists have been seeking a method to stimulate T helper cells in
a manner that directs the immune response away from the allergic
pattern. Allergy symptoms arise when a T helper cell type 2 (TH2)
response occurs to an environmental antigen, stimulating production
of immunoglobulin E (IgE). When IgE is crosslinked by recognition of
an allergen protein, on the surface of mast cells and basophils,
histamine and other mediators of allergy are released. A wide range
of responses can be found ranging from local redness and swelling in
the skin, itchy nose, ears, roof of mouth, watery eyes and sneezing,
to severe bronchoconstriction requiring powerful medicines and
potentially intubation and respiratory support.

Antigen Express scientists have found that their established
approach to stimulating responses to cancer and infectious disease
antigens stimulates a strong TH1 response, away from a TH2 response.
That is exactly the pattern sought in research studies to tune down
allergic reactions. This method of treatment goes directly to the
cause of the allergic response, rather than just treatment of
symptoms.

"Since my days in the Allergy Clinic of the Bethesda Naval Hospital,
trying to help patients with moderate to severe forms of allergy and
asthma, I have followed the scientific and clinical literature
toward making some better product," said Robert Humphreys, M.D.,
Ph.D., the Chief Scientific Officer of Antigen Express. He feels now
that he might just have that better product to control allergic
reactions. Nevertheless, "A lot of work lies ahead, in collaboration
with skilled researchers and clinicians working in allergy."

In collaboration with Dr. Philippe Moingeon, Director of Research
and Development at Stallergenes, Dr. Humphreys has designed a series
of

Ii-Key/allergic epitope hybrid peptides for assays in France, using
both lymphocytes from allergic patients and in mouse animal models.
Dr. Moingeon said, "Bob Humphreys has developed a novel approach to
controlling allergy. We seek to test it further in the laboratory,
to see if basic biological mechanisms support further work toward
clinical trials. Potential advantages lie in the use of peptide
fragments of the allergen, not recognized by IgE, and in the
enhanced potency of the epitope so that therapy can be at very small
doses."

About Generex

Generex is engaged in the research and development of drug delivery
systems and technologies. Generex has developed a proprietary
platform technology for the delivery of drugs into the human body
through the oral cavity (with no deposit in the lungs). The
Company's proprietary liquid formulations allow drugs typically
administered by injection to be absorbed into the body by the lining
of the inner mouth using the Company's proprietary RapidMist(TM)
device. The Company's flagship product, oral insulin (Oral- lyn
(TM)), which has been approved for commercial sale in Ecuador for
the treatment of patients with Type-1 and Type-2 diabetes, is in
various stages of clinical trials around the world. Generex acquired
Antigen Express in August, 2003. The core platform technologies of
Antigen Express comprise immunotherapeutics for the treatment of
malignant, infectious, allergic, and autoimmune diseases.

For more information, visit the Generex Web site at
http://www.generex.com.

Safe Harbor Statement: This release and oral statements made from
time to time by Generex representatives concerning the same subject
matter may contain "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. These
statements can be identified by introductory words such
as "expects," "plans," "intends," "believes," "will," "estimates," "f
orecasts," "projects" or words of similar meaning, and by the fact
that they do not relate strictly to historical or current facts.
Forward-looking statements frequently are used in discussing
potential product applications, potential collaborations, product
development activities, clinical studies, regulatory submissions and
approvals, and similar operating matters. Many factors may cause
actual results to differ from forward-looking statements, including
inaccurate assumptions and a broad variety of risks and
uncertainties, some of which are known and others of which are not.
Known risks and uncertainties include those identified from time to
time in the reports filed by Generex with the Securities and
Exchange Commission, which should be considered together with any
forward-looking statement. No forward- looking statement is a
guarantee of future results or events, and one should avoid placing
undue reliance on such statements. Generex claims the protection of
the safe harbor for forward-looking statements that is contained in
the Private Securities Litigation Reform Act.

---------------------------------------------------------------------
-----------
Source: Generex Biotechnology Corporation

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.azhttp.com/
http://www.arizonaentrepreneurs.com/

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

United BioSource Corporation (UBC) New Blog Addresses Pharmaceutical and Biotechnology Reimbursement Issues

United BioSource Corporation (UBC) New Blog Addresses Pharmaceutical and Biotechnology Reimbursement Issues

- Experts with Diverse Perspectives to Provide Commentary and Analysis -

A new blog will provide expert commentary and analysis regarding third-party payer reimbursement for prescription drugs, particularly by the Medicare and Medicaid programs. The "Access Matters" blog is sponsored by United BioSource Corporation (UBC), and will feature commentary and analysis by reimbursement specialists, and other health care experts with leadership experience in key government agencies such as the Centers for Medicare and Medicaid Services (CMS) and state Medicaid agencies.
Access Matters is targeted to pharmaceutical and biotechnology industry insiders who are interested in the latest news and developments regarding reimbursement for prescription drugs by government health care programs and commercial health insurance companies.

The blog is available at http://accessmatters.unitedbiosource.com

"The issues surrounding reimbursement for prescription drugs, particularly by the large government health insurance programs such as Medicare and Medicaid, are vitally important, yet very complicated," said Ethan Leder, CEO of UBC. "Bringing together experts to comment on these issues and highlight important developments will help to better inform and educate everyone in the industry. Whether the issue is the new prescription drug benefit under Medicare, or the proliferation of Medicaid cost-cutting tactics such as preferred drug lists, tiered co-payments, or prior authorization, the Access Matters blog will provide expert insight and interesting perspectives."

The contributors to Access Matters represent diverse perspectives in the health care community, including key government agencies, academia, and manufacturers of prescription drugs, biotechnology and other medical technology. Among the contributors are:

* Ruben J. King-Shaw, Jr. -- Health care private equity investor who
formerly served as the Deputy Administrator and COO of the Centers for
Medicare and Medicaid Services at the Department of Health and Human
Services. Prior to joining the Bush Administration, Mr. King-Shaw was
the Secretary of the Florida Agency for Health Care Administration.

* Bryan R. Luce, Ph.D., M.B.A. -- Founder and Senior Research Leader for
The MEDTAP® Institute at UBC, and Director, Science Policy at UBC.
Dr. Luce is also a member of the Medicare Coverage Advisory Committee,
a past president of the International Society of Pharmacoeconomics and
Outcomes Research (ISPOR) and has held positions as Director of
Battelle's Centers for Public Health Research and Evaluation, Director
of the Office of Research and Demonstrations, Health Care Financing
Administration and Senior Analyst for the former Office of Technology
Assessment for the United States Congress.

* Diane L. Simison, Ph.D. -- Executive Director of The MEDTAP®
Institute at UBC's Center for Pricing and Reimbursement. Dr. Simison
leads the Center's reimbursement team. She has 13 years of experience
in reimbursement for the pharmaceutical industry, 20 years experience
in pharmaceutical market research, and 30 years of experience in health
research management for private industry. Her expertise includes
coverage and payment for pharmaceuticals, managed care market research,
launch-to-payers planning, payment issues and barrier analysis, payer
education and advocacy.

About UBC
United BioSource Corporation (UBC) delivers evidence-based solutions to optimize the medical and commercial potential of pharmaceuticals, biotechnology, medical devices, and diagnostics. UBC is based in Bethesda, Maryland. For more information about UBC, visit http://www.unitedbiosource.com or call 240-644-0420.

--------------------------------------------------------------------------------
Source: United BioSource Corporation

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Australia Recognized Globally as Stem Cell Research Hub

Australia Recognized Globally as Stem Cell Research Hub
Wednesday June 22, 8:08 am ET
Government funding and supportive legislation backs nation's stem
cell research excellence

Australia, known globally for its biotech R&D capabilities and
strengths in human therapeutics, agribiotech, diagnostics, medical
devices and biodiscovery, will has some of its best in stem cell
research capabilities on show at BIO 2005.
While human cloning is currently prohibited in Australia, embryonic
and adult stem cell research is allowed. Australia continues to lead
the world in stem cell research with innovative programs now
underway to develop potential treatments for diabetes, Parkinson's
and heart disease.

Studies currently underway at Australia's government backed
Australian Stem Cell Centre [ASCC], and some of its collaborative
partner institutions, include development of potential therapies for:

* Congestive cardiac failure
* Hematological disorders
* Respiratory diseases
* Disease and injury of the kidney

The ASCC announced at BIO 2005 that, as testament to the nation's
standing in the stem cell arena, the International Society for Stem
Cell Research's annual meeting will, for the first time meet outside
North America -- in the Australian city of Cairns in the State of
Queensland, in 2007.

Dr Anna Lavelle, the newly appointed Chief Executive Officer of
AusBiotech, Australia's peak biotech industry organization, said
Australia has been actively involved in R&D in this area.

In 1980 the first IVF birth in Australia was reported. In 1983
Australia announced the world's first egg donor baby and the
development of embryo freezing technology that resulted in the first
frozen embryo baby.

"Since then Australian IVF and stem cell research teams have clocked
advances in this sector with world-class research and solid
government backing aimed at creating therapies for real health
issues facing Australians -- and the world," said Dr Lavelle.

To make an appointment with members of the Australian delegation
please go to Austrade's online diary and select the Business
Matching service where your request will be confirmed within 24
hours: www.austrade.gov.au/bio2005/.

For a listing of the 63 Australian exhibitors at BIO2005, please
visit the Australian Exhibitor section of Invest Australia's BIO
2005 website at www.investaustralia.gov.au/biotech/bio2005 .

About AusBiotech -- www.ausbiotech.org

AusBiotech is Australia's biotechnology industry organization, which
represents over 2,400 members, covering the human health,
agricultural, medical device, environmental and industrial sectors
in biotechnology.

AusBiotech is dedicated to the development, growth and prosperity of
the Australian biotechnology sector, by providing initiatives to
drive sustainability and growth, outreach and access to markets, and
representation and support for members nationally and around the
world.

AusBiotech has representation in each Australian State and provides
the foundation to bring together all the relevant players to
facilitate the commercialization of Australian bioscience in the
national and international marketplaces. The structure is a not-for-
profit limited guarantee company managed by a Board elected by
members, under a constitution that is available on request from
National Office.

AusBiotech's membership base includes biotechnology companies,
ranging from start-ups to mature multinationals, research institutes
and universities, specialist service professionals, corporate,
institutional, individual and student members from Australia and
globally.

About Invest Australia -- www.investaustralia.gov.au/biotech

Invest Australia is Australia's national inward investment agency,
set up by the Australian Federal Government in 1997, to attract
productive foreign direct investment into Australia to support
sustainable industry growth and development. Invest Australia has
investment advisory specialists in 11 locations around the world,
including San Francisco and New York, to provide investors with on-
the-ground support and investment advice, including free and
confidential advice to firms to help find the right business
partners and identify commercial opportunities. In the past two
financial years, to June 2004, Invest Australia has played a role in
attracting 105 projects worth US$11.1 billion, involving 9,470 jobs.

About Austrade -- www.austrade.gov.au

The Australian Trade Commission, Austrade, is the Federal Government
agency that helps Australian companies win overseas business for
their products and service by reducing the time, cost and risk
involved in selecting and developing international markets.
Biotechnology is as a major source of growth for Australian industry
and as such Austrade has established a specialist Biotech team.

Austrade, with seven offices in the US, can assist international
biotechnology companies to partner with Australia's leading
biotechnology companies and clusters of excellence.

About the Australian Stem Cell Centre -- www.stemcellcentre.edu.au

The Australian Stem Cell Centre is a major Australian collaborative
initiative uniting many of the country's leading academic
researchers with the biotechnology industry to develop innovative
therapeutic products to treat blood and heart diseases.

The Centre will build on Australia's existing expertise in stem cell
and related platform technologies to lay the foundations for
delivering stem cell therapies.

---------------------------------------------------------------------
-----------
Source: AusBiotech

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.azhttp.com/
http://www.arizonaentrepreneurs.com/

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] New Study Shows Embryonic Stem Cell Lines Classified by ``MicroRNA'' Expression;

New Study Shows Embryonic Stem Cell Lines Classified by ``MicroRNA''
Expression; Applied Biosystems TaqMan MicroRNA Assays Quantify
Minute Changes in MicroRNA Expression during Stem Cell
Differentiation

Results May Have Implications in Determining Optimal Stem Cell Lines
for Therapeutic Research

In conjunction with the International Society for Stem Cell Research
(ISSCR) Annual Meeting, Applied Biosystems Group (NYSE:ABI), an
Applera Corporation business, and the University of Colorado today
presented data using a preliminary version of Applied Biosystems
TaqMan(R) MicroRNA Assays to profile microRNA (miRNA) expression in
mouse stem cells.

The collaborative research study shows embryonic stem cells can be
classified according to miRNA expression profiles, potentially
having implications in determining optimal stem cell lines. Using
TaqMan miRNA assays, researchers were able to accurately determine
expression levels across a large panel of miRNAs and reveal precise
changes in individual miRNA expression during stem cell
differentiation. The assays discriminated between miRNAs differing
by as little as a single nucleotide and between mature miRNAs and
their precursors, even in single cells.

Increasing evidence indicates miRNAs, a recently discovered class of
small RNA molecules, play a powerful gene regulatory role in cell
differentiation and developmental biology, cancer, and other
diseases.

"The different microRNA expression profiles in embryonic stem cells
suggest some embryonic cell cultures may contain variable
subpopulations of spontaneously differentiated cells," said William
M. Strauss, Ph.D., Assistant Research Professor, Department of
Molecular, Chemical and Developmental Biology (MCDB), University of
Colorado, Boulder. "Our newly identified microRNAs could one day be
used as molecular markers for monitoring differentiation within
embryonic stem cell lines."

Researchers examined the expression levels of 252 mouse and human
miRNAs in four mouse embryonic stem cell lines, differentiated
embryoid bodies, and six mouse tissues. Preliminary results found
embryonic stem cells could be accurately classified and
differentiated from embryoid bodies and adult tissue using their
distinct miRNA expression signatures.

"We are excited about the potential of our novel TaqMan(R) MicroRNA
Assays to provide further insights about the role of miRNAs in cell
differentiation," said Dennis Gilbert, Ph.D., Chief Scientific
Officer, Applied Biosystems. "This is the first time a technology
has been able to quantify miRNAs easily and accurately using
starting samples as small as a single cell. These findings may hold
promise for stem cell researchers as they identify optimal cell
lines for use in therapeutic research."

In addition, data showed a total of 55 percent (138) of miRNAs
studied were up-regulated by more than a fold, while only one
percent (3) were down-regulated during the development of embryonic
stem cells into embryoid bodies, suggesting miRNA expression levels
globally increase during embryonic stem cell differentiation and may
play an important role in activating lineage-specific genes.

Applied Biosystems TaqMan(R) MicroRNA Assays distinguish between
mature miRNAs and their precursor form by using a proprietary stem-
loop technology for reverse transcription (RT) of the mature miRNA,
followed by quantitative real-time PCR. Applied Biosystems currently
has a large set of the miRNA assays in development and plans to
commercialize its miRNA assay technology based on TaqMan(R) 5'
nuclease chemistry for real-time PCR.

The poster (#53), titled "TaqMan-Based MiRNA Profiles Classify
Embryonic Stem Cells (ES) and Differentiated Cells," will be
presented at ISSCR today, June 23, from 5:30 to 7 p.m. and during an
ISSCR tutorial, titled "Real-Time PCR Applications for Stem Cell
Research," from 7 to 8 p.m. To register for the tutorial go to
http://info.appliedbiosystems.com/isscr. A copy of the poster can be
downloaded at http://miRNA.appliedbiosystems.com.

About University of Colorado

The University of Colorado is a three-campus system with campuses in
Boulder and Colorado Springs, and the recently consolidated Denver
and Health Sciences Center campuses located in Denver and at the
former Fitzsimons Army Base in Aurora. For further information,
please contact Michele McKinney in the CU System Office of
Institutional Relations at (303) 492-6206.

About Applera Corporation and Applied Biosystems

Applera Corporation consists of two operating groups. The Applied
Biosystems Group serves the life science industry and research
community by developing and marketing instrument-based systems,
consumables, software, and services. Customers use these tools to
analyze nucleic acids (DNA and RNA), small molecules, and proteins
to make scientific discoveries, develop new pharmaceuticals, and
conduct standardized testing. Applied Biosystems is headquartered in
Foster City, CA, and reported sales of $1.7 billion during fiscal
2004. The Celera Genomics Group (NYSE:CRA) is engaged principally in
the discovery and development of targeted therapeutics for cancer,
autoimmune and inflammatory diseases. Celera Genomics is leveraging
its proteomic, bioinformatic, and genomic capabilities to identify
and validate drug targets, and to discover and develop small
molecule therapeutics. It is also seeking to advance therapeutic
antibody and selected small molecule drug programs in collaboration
with global technology and market leaders. Celera Diagnostics, a
50/50 joint venture between Applied Biosystems and Celera Genomics,
is focused on discovery, development, and commercialization of
diagnostic products. Information about Applera Corporation,
including reports and other information filed by the company with
the Securities and Exchange Commission, is available at
http://www.applera.com, or by telephoning 800.762.6923. Information
about Applied Biosystems is available at www.appliedbiosystems.com.

Applied Biosystems Forward Looking Statements

Certain statements in this press release are forward-looking. These
may be identified by the use of forward-looking words or phrases
such as "plan," "expect," and "should," among others. These forward-
looking statements are based on Applera Corporation's current
expectations. The Private Securities Litigation Reform Act of 1995
provides a "safe harbor" for such forward-looking statements. In
order to comply with the terms of the safe harbor, Applera
Corporation notes that a variety of factors could cause actual
results and experience to differ materially from the anticipated
results or other expectations expressed in such forward-looking
statements. These factors include but are not limited to (1) rapidly
changing technology and dependence on the development and customer
acceptance of new products; (2) sales dependent on customers'
capital spending policies and government-sponsored research; (3)
Applied Biosystems' dependence on the operation of computer
hardware, software, and Internet applications and related
technology; (4) unproven use of genomics information to develop or
commercialize products; and (5) other factors that might be
described from time to time in Applera Corporation's filings with
the Securities and Exchange Commission. All information in this
press release is as of the date of the release, and Applera does not
undertake any duty to update this information, including any forward-
looking statements, unless required by law.

For Research Use Only. Not for use in diagnostic procedures.

The PCR process and the 5' nuclease process are covered by patents
owned by Roche Molecular Systems, Inc. and F. Hoffmann-La Roche Ltd.

Copyright(C) 2005. Applera Corporation. All rights reserved. Applied
Biosystems and Celera are registered trademarks and Applera is a
trademark of Applera Corporation or its subsidiaries in the U.S.
and/or certain other countries. TaqMan is a registered trademark of
Roche Molecular systems, Inc.

Contacts

Applied Biosystems
Sophie Patel, 650-554-2732 (Media)
sophia.patel@appliedbiosystems.com
Peter Dworkin, 650-554-2479 (Investors)
dworkipg@appliedbiosystems.com
European Media and Investors
David Speechly, Ph.D., (+) 44.162.273.9150
speechdp@eur.appliedbiosystems.com

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.azhttp.com/
http://www.arizonaentrepreneurs.com/

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Combating Cancer with Gene Therapy

Combating Cancer with Gene Therapy

Frost & Sullivan to Host Interactive Quarterly Analyst Briefing on
Gene Therapy in the Cancer Treatment Markets on Tuesday, June 28,
2005.

The Technical Insights group at Frost & Sullivan is pleased to
announce its exclusive 2005 Quarterly Industry Analyst Briefing on
gene therapy in the cancer treatment market to be held on Tuesday,
June 28, 2005 at 1:00pm EDT / 12:00pm CDT.

The briefing will provide manufacturers, researchers in
pharmaceutical and biotech companies and other industry participants
with an overview of the current state of gene-therapy technologies
focused on the treatment of cancer. The briefing will discuss
various types of technologies under development for improved gene
delivery and different gene therapy approaches for selective killing
of tumor cells. Highlights of the briefing include technology
overview, industry trends, key drivers, barriers to
commercialization and an insight into important clinical trails.

"Cancer continues to be the primary target for gene therapy with
more than 2.5 million new cases of cancer diagnosed each year
worldwide. Today an increased knowledge about the role of genes in
cancer has led to the development of novel cancer therapies," says
Frost & Sullivan Technical Insights Research Analyst, A.N. Aditya.

The presentation will discuss some of the latest happenings and
technology trends in this sector. Government, public and private
initiatives will also be discussed. This free teleconference will
cover the overview of the gene therapy in the cancer treatment
market, the future outlook of emerging technologies and an
interactive question and answer session.

Those interested in participating in this exclusive analyst briefing
should send an email to Danielle White, dwhite@frost.com, with the
following information for registration: full Name, company name,
title, telephone number, fax number, city, state, address, and email
address. Upon receipt of the above information, a confirmation/pass
code for the live briefing will be emailed to you.

Frost & Sullivan, a global growth consulting company, has been
partnering with clients to support the development of innovative
strategies for more than 40 years. The company's industry expertise
integrates growth consulting, growth partnership services, and
corporate management training to identify and develop opportunities.
Frost & Sullivan serves an extensive clientele that includes Global
1000 companies, emerging companies, and the investment community by
providing comprehensive industry coverage that reflects a unique
global perspective and combines ongoing analysis of markets,
technologies, econometrics, and demographics. For more information,
visit http://www.frost.com.

Contacts

Frost & Sullivan, San Antonio
Corporate Communications - Healthcare
Danielle White, 210-247-2403
dwhite@frost.com
http://www.frost.com

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.azhttp.com/

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

NASA, Entrepreneurs to Develop Biotechnology Plan for Space Station | SpaceRef - Your Space Reference

NASA, Entrepreneurs to Develop Biotechnology Plan for Space Station | SpaceRef - Your Space Reference

NASA, Entrepreneurs to Develop Biotechnology Plan for Space Station

NASA scientists and space service providers are meeting on June 21 and June 22 to develop a new entrepreneurial paradigm for the International Space Station (ISS) focusing on biotechnology applications.

The workshop is being held at the Santa Clara Convention Center, 5001 Great America Parkway, Santa Clara, Calif. Seminar participants will help evaluate the business case and feasibility for commercial endeavors on the ISS and report their findings and conclusions in open session. A formal report will be presented to the NASA Administrator by mid-July 2005.

"NASA will reach out to the private sector and look for ways to collaborate," said NASA Administrator Mike Griffin. "I hope this workshop is successful."

"Until recently, the business case for commercial endeavors on the International Space Station was not compelling," said G. Scott Hubbard, director of NASA Ames Research Center. "But recent information shows that the space environment and the International Space Station may offer an important, and as yet undeveloped, new intellectual property arena for biotech. Emerging launch industries, advances in biotech, improvements in automation, and innovative concepts for returning samples from space offer new opportunities to solve the throughput problem that has been the major impediment to space biotech development," he added.

For information about the New Entrepreneurial Paradigm for the International Space Station workshop, visit:

http://issworkshop.arc.nasa.gov

For information about NASA and agency programs on the Internet, visit:

http://www.nasa.gov

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Curis to Present at the Bear Stearns Boston Biotech Confab

Curis to Present at the Bear Stearns Boston Biotech Confab

CAMBRIDGE, Mass.
Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company,
today announced that the Company will be presenting at the Bear
Stearns Boston Biotech Confab on Tuesday, June 28, at the Hyatt
Regency in Cambridge, Massachusetts.

Daniel Passeri, Curis' President and Chief Executive Officer, will
provide an overview of the status of Curis' business and
collaborations at 3:05 p.m. Eastern. There will be an audio webcast
of the presentation at:
customer.talkpoint.com/BEAR002/062805a_cy/default.asp?entity=curis
(Due to its length, this URL may need to be copied/pasted into your
Internet browser's address field. Remove the extra space if one
exists.)

The presentation will be archived shortly after the live event and
available for 30 days following the conference. The presentation
will also be available on the Investor Relations section of Curis'
website at www.curis.com.

About Curis, Inc.

Curis, Inc. is a therapeutic drug development company. The Company's
technology focus is on regulatory pathways that control repair and
regeneration. Curis' product development involves the use of
proteins or small molecules to modulate these pathways. Curis has
successfully used this technology and product development approach
to produce several promising drug product candidates in the fields
of cancer (under collaboration with Genentech, which also includes a
co-development arrangement for a basal cell carcinoma product
candidate), kidney disease (licensed to Ortho Biotech Products and
under development at Centocor, both subsidiaries of Johnson &
Johnson), neurological disorders (under collaboration with Wyeth),
hair growth, and cardiovascular disease. For more information,
please visit the Curis web site at www.curis.com.

Contacts

Curis, Inc.
Chief Financial Officer
Michael P. Gray, 617-503-6632
or
Director, Corporate Communications
Megan E. Burling, 617-503-6658

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Berna Biotech Announces Two New Collaborations

Berna Biotech Announces Two New Collaborations

· with the Australian-based biopharmaceutical company CSL regarding
Aerugen for Australia and New Zealand

· with the Swiss-based biopharmaceutical company Apoxis regarding
recombinant protein production

BERNE, Switzerland, June 22, 2005--Berna Biotech Ltd (SWX: BBIN)
announced today two new collaborations:

With CSL an exclusive commercialisation and licence agreement for
AerugenÒ in Australia and New Zealand was signed. AerugenÒ is a
vaccine for the prophylaxis of Pseudomonas aeruginosa infections in
cystic fibrosis patients and is expected to be launched in Europe in
the year 2007.

CSL Limited is a global, specialty biopharmaceutical company that
develops, manufactures and markets products to treat and prevent
serious human medical conditions; Headquartered in Melbourne
Australia, the CSL Group includes CSL Bioplasma, CSL Pharmaceutical
and ZLB Behring incorporating ZLB Plasma Services.

With Apoxis an agreement for clinical-grade, recombinant protein
production and supply was signed: Berna will apply its mammalian-
cell process development expertise and state-of-the-art
manufacturing facility to the production of Apoxis' recombinant
MegaFasL product for phase I clinical trials in oncology.

Apoxis SA is a Swiss-based biopharmaceutical company. Apoxis
develops novel therapeutic proteins able to modulate apoptotic cell
death (cell suicide). Apoptosis plays a central role in the
regulation of cancer and autoimmune disease and its control, through
agonistic or antagonistic molecules, holds great promise for the
treatment of life-threatening diseases. For further information see
http://www.apoxis.com

No financial details were disclosed.

For further information:

Berna Biotech Ltd
Patrik Richard
Corporate Secretary
communications@bernabiotech.com
Phone +41 (0) 31 980 64 91
www.bernabiotech.com

CSL Ltd
Dr Rachel David
Director, Public Affairs
rachel.david@csl.com.au
Phone 0401 775 779
www.csl.com.au

Apoxis SA
Cedric Haenni
Chief Operation Officer
haenni@apoxis.com
Phone: +41 (0)21 620 60 82
www.apoxis.com

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Bristol-Myers Squibb Company Signs Manufacturing Agreement With Celltrion

Bristol-Myers Squibb Company Signs Manufacturing Agreement With
Celltrion
Tuesday June 21, 10:00 pm ET
- Celltrion To Produce Select Biologic Products -

PRINCETON, N.J., June 21 /PRNewswire-FirstCall/ -- Bristol-Myers
Squibb Company (NYSE: BMY - News) announced today that it has
completed an agreement with Celltrion, Inc. for Celltrion to
manufacture biologic products being developed by Bristol-Myers
Squibb. Commercial terms of the agreement were not disclosed.
ADVERTISEMENT

"A key element of our company strategy is the expansion of our
portfolio of biologic products. In support of that goal we must
continuously assess our manufacturing capabilities," said Carlo de
Notaristefani, president, Technical Operations, Bristol-Myers
Squibb. "Bristol-Myers Squibb has several biologic products in
various stages of development, including the late stage products
abatacept and belatacept. This agreement increases our biologic
manufacturing capacity to help ensure sufficient long-term supply of
our products."

The Celltrion facility, located in Incheon, South Korea, is capable
of producing multiple products, including abatacept and belatacept.
This agreement adds to Bristol-Myers Squibb's existing biologic
manufacturing capacity, which includes a biologic manufacturing
facility in Syracuse, NY owned and operated by the company and a
previously announced biologics manufacturing agreement with Lonza
Biologics PLC.

Bristol-Myers Squibb is a global pharmaceutical and related health
care products company whose mission is to extend and enhance human
life.

Bristol-Myers Squibb Forward-Looking Statement

This press release contains certain forward-looking information
within the meaning of the Private Securities Litigation Reform Act
of 1995 regarding a product in development and the potential
efficacy of such product that involves substantial risks and
uncertainties. Such risks and uncertainties include, among other
things, the uncertainty of the success of the research and
development activities; decisions by regulatory authorities
regarding whether and when to approve any new drug application for a
product candidate that may result from the research, as well as
their decisions regarding labeling and other matters that could
affect the commercial potential of such product candidate; and
competitive developments. A further list and description of risks
and uncertainties can be found in the Bristol-Myers Squibb's Annual
Report on Form 10-K for the fiscal year ended December 31, 2004, and
in its reports on Form 10-Q and Form 8-K. The Company undertakes no
obligation to publicly update any forward-looking statement, whether
as a result of new information, future events or otherwise.

---------------------------------------------------------------------
-----------
Source: Bristol-Myers Squibb

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Stem Cell Conference Opens in California By PAUL ELIAS

Stem Cell Conference Opens in California By PAUL ELIAS
Thursday, June 23, 2005 11:05 AM EDT

Petoskey News-Review

SAN FRANCISCO - Despite optimism and enthusiasm, stem cell researchers arriving here Thursday for a conference are rowing hard against strong currents of financial, political and technical turmoil.

There's even talk of trying to temper heightened public expectations that cures for diseases are imminent.

"Many of the technologies we hyped to the general public haven't worked yet," Celgene Corp. President Alan Lewis said Wednesday at a biotechnology trade show in Philadelphia. He also noted that venture capitalists "are very cautious" about investing in stem cell companies because of uncertainty over the field's future.

Still, hope springs eternal among the world's best cloners and stem cell researchers gathering in San Francisco on Thursday to show off their latest breakthroughs at the biggest professional conference on the topic to date.

The more than 1,000 researchers set to attend are excited by the prospect that they can someday coax _ on command _ stem cells to regenerate into spare body parts to heal the sick and injured.

"Stem cell research is the hottest thing in science right now," said Leonard Zon, president of the International Society for Stem Cell Research, which is hosting the conference dedicated to one of the most controversial issues in science.

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Wednesday, June 22, 2005

[ biotech news ] Biotech Breakthrough Will Favorably Impact the U.S. Chemical Industry

Biotech Breakthrough Will Favorably Impact the U.S. Chemical Industry

Codexis and Cargill, members of the Biotechnology Industry
Organization's (BIO) Industrial and Environmental Section, today
announced a breakthrough in developing a novel microbial process
that will convert corn sugar to a chemical intermediate. This
process is an important milestone in the development of a new
renewable chemical platform. When fully commercialized, the
industrial biotech process will convert dextrose derived from corn
to a chemical intermediate known as 3, hydroxyproprionic acid (3HP).

The new process will utilize very low-cost, clean agricultural
feedstocks instead of petroleum to produce 3HP. 3HP is a key
intermediate for several commercially important chemicals. The
chemicals that can be produced from 3HP include acrylic acid,
acrylamide and 1,3 propanediol. Acrylic acid and its derivatives are
used to create a wide range of polymer-based consumer and industrial
products, such as adhesives, paints, polishes, protective coatings,
and sealants. This new process is cheaper and more environmentally
friendly than the old process that uses petroleum as a feedstock.

"Industrial biotechnology converges seamlessly with other scientific
disciplines and is a powerful source of innovation for new products
and processes," stated Brent Erickson, executive vice president for
BIO's Industrial and Environmental Section. "The global acrylic acid
market is worth over $4 billion. This breakthrough is going to shake
up the chemical industry and it will help U.S. companies that adopt
it to be more competitive in the global marketplace."

"With natural gas and crude oil prices going through the roof, the
commercialization of this renewable chemical platform should be
great news for the chemical industry. The chemical industry needs
new feedstocks to stay competitive, and this chemical platform will
be based on corn, not foreign oil. Furthermore, the biobased economy
that is evolving is about more than just ethanol," Erickson
added. "The interface between industrial biotechnology and
agricultural production provides the ability to produce inexpensive,
natural raw materials -- such as sugars and lipids -- for
manufacturing biobased products. Sugars and lipids from agricultural
crops can be used in many products, replacing increasingly expensive
oil and natural gas, which are currently the main feedstocks of the
chemical industry," Erickson continued.

BIO represents more than 1,100 biotechnology companies, academic
institutions, state biotechnology centers and related organizations
across the United States and 31 other nations. BIO members are
involved in the research and development of healthcare,
agricultural, industrial and environmental biotechnology products.

---------------------------------------------------------------------
-----------
Source: Biotechnology Industry Organization

http://www.arizonabiotech.com/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://groups.yahoo.com/group/biotech-news/

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] FierceBiotech Honors Xencor as One of the ``Fierce 15'' Biotech Companies of 200

FierceBiotech Honors Xencor as One of the ``Fierce 15'' Biotech
Companies of 2005

Xencor, Inc., a company engineering superior biotherapeutics using
its Protein Design Automation(R) technology, announced today that it
has been selected as one of the "Fierce 15" for 2005 by
FierceBiotech, an internationally recognized publication for the
biotech industry covering the biotechnology and pharmaceutical
markets. Xencor was chosen as one of the top emerging biotechnology
companies for the company's innovative Protein Design Automation (PDA
(R)) technologies, including Xencor's XmAb(TM) technology that
improves the potency of monoclonal antibodies.

"The beauty of Xencor's work is that it focuses on the constant
region of an antibody, redesigning a segment that helps it more
effectively attack a target cell by improving an antibody's natural
immune system recruitment," says John Carroll, of
FierceBiotech. "Like the other swiftly developing companies on this
year's Fierce 15 list, we'll be watching Xencor closely in the years
ahead."

"Xencor's PDA technology has allowed the company to generate an
outstanding roster of industrial collaborators and grow an internal
pipeline of biotherapeutics, with our lead candidate for the
treatment of rheumatoid arthritis, DN-TNF, expected to enter human
trials in 2006," said Bassil Dahiyat, President and CEO of
Xencor. "Xencor is honored to be chosen for this distinction by
FierceBiotech, a recognized leader in the industry for advancing an
understanding of biotechnology companies and the life science
community."

The Fierce 15 celebrates the spirit of being "fierce" -- championing
innovation and creativity, even in the face of intense competition.
The list of Fierce 15 companies is available in today's issue of
FierceBiotech and on the FierceBiotech Web site at
http://www.fiercebiotech.com.

About FierceBiotech

FierceBiotech, an internationally recognized email newsletter for
the biotech industry, provides more than 35,000 executives a must-
read briefing on the day's top stories in the biotech and
pharmaceutical industries. Visit http://www.fiercebiotech.com for
additional information.

About Xencor

Xencor, Inc., engineers biotherapeutics including protein
therapeutic candidates and XmAb(TM) antibody drug candidates using
its proprietary Protein Design Automation(R) technology platform.
The company is internally advancing several therapeutics against
biologically validated targets, including a protein therapeutic drug
candidate for the treatment of arthritis and other rheumatic
disorders and antibody candidates for the treatment of cancer. With
multiple partners such as industry leaders Genentech and Roche,
Xencor applies its suite of XmAb antibody Fc domains to improve
antibody drug candidates for traits such as potency, affinity, and
stability. Xencor also develops therapeutic protein variants in
collaboration with major pharmaceutical partners. For more
information, please visit www.xencor.com.

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Berna Biotech Enters Australia, Swiss Cooperations

Berna Biotech Enters Australia, Swiss Cooperations

Swiss biotechnology company Berna Biotech AG (BBIN.EB) Wednesday
said it entered new cooperations with Australia-based CSL Ltd
(CSL.AU) and Swiss company Apoxis.

Berna Biotech entered an exclusive commercialization and licence
agreement for Aerugen in Australia and New Zealand with CSL. Aerugen
is a vaccine for the prophylaxis of Pseudomonas aeruginosa
infections in cystic fibrosis patients and is expected to be
launched in Europe in the year 2007.

Melbourne-based CSL is a biopharmaceutical company that develops,
manufactures and markets products to treat and prevent serious human
medical conditions.

With Apoxis an agreement for clinical-grade, recombinant protein
production and supply was signed. Berna Biotech will help in the
production of Apoxis' produce recombinant MegaFasL product for phase
I clinical trials in oncology.

Apoxis develops novel therapeutic proteins able to modulate
apoptotic cell death, or cell suicide. Apoptosis plays a central
role in the regulation of cancer and autoimmune disease and its
control, through agonistic or antagonistic molecules, holds great
promise for the treatment of life-threatening diseases.

http://www.bernabiotech.com

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Tuesday, June 21, 2005

[ biotech news ] BIO Ventures for Global Health Announces Bill & Melinda Gates Foundation Grant t

BIO Ventures for Global Health Announces Bill & Melinda Gates
Foundation Grant to Expand Biotech Industry's Role in Fight Against
Neglected Diseases

Four-year, $5.4 Million Grant Will Help Companies Overcome Market
and Funding Barriers

PHILADELPHIA, June 21 BIO Ventures for Global Health today announced
it will expand its efforts to enlist biotechnology companies in the
fight to improve global health, with a new $5.4 million grant from
the Bill & Melinda Gates Foundation. BVGH is a nonprofit venture
founded last year by the Biotechnology Industry Organization, with
support from the Gates Foundation and the Rockefeller Foundation.
The announcement was made at BIO 2005, the biotech industry's annual
convention.

"The biotech industry has tremendous potential for developing new
therapeutics, vaccines and diagnostics against diseases of the
developing world," said Richard Klausner, MD, executive director of
the Gates Foundation's Global Health program. "For too long,
funding, market, and information barriers have prevented biotech
companies from realizing this potential. We believe that BIO
Ventures for Global Health will provide the means to help industry
overcome some of these barriers. We congratulate BVGH in taking
leadership in helping to bring the potential of biotechnology to
improving health equity in our world."

The new grant will help BVGH launch a series of business cases to
assess and build market opportunities for neglected diseases.
Companies are deterred by an insufficient understanding of
developing world markets and many lack the capacity to generate this
knowledge on their own. To evaluate whether to invest in a
technology, they need information on potential market demand and
pathways to get products tested, licensed and distributed. BVGH will
fill that gap. The business cases, a tool used regularly by
industry, will explore new models for tapping into emerging markets.
BVGH's first business case will evaluate the market opportunity for
tuberculosis vaccines.

"This grant represents a historic shift in thinking about how to
engage the biopharma sector in addressing the unmet health needs of
people in developing countries," said Rob Chess, Chairman of
BVGH. "We understand the business of biotech and are seeking ways to
translate that knowledge into solutions that improve the lives of
individuals in the poorest regions of the world."

For markets that are too small to compete with other industry
opportunities, BVGH will pursue market incentives to enhance the
underlying market and "pull" new industry investment. Over the last
year, BVGH has reached out aggressively to biotechnology companies
and has represented the industry in talks with the World Bank and
the finance ministers of the G7 countries to design advance market
commitments to spur biotech innovation for critical products such as
AIDS and malaria vaccines.

"BVGH is uniquely placed, with access to -- and intellectual support
from -- the most innovative biopharma companies -- large and small,"
said Jim Greenwood, President of the Biotechnology Industry
Organization. "BVGH has treated global health as a business from the
outset, and funding for their efforts should have a catalytic impact
on industry's response to these immense global challenges."

Currently, less than 10 percent of health research funding is
targeted to diseases that account for 90 percent of the global
disease burden. BVGH aims to radically change that equation.

"The biopharma industry is ready and willing to tackle the tough
scientific and technical challenges in global health, but the market
has to be there," said BVGH Executive Director Wendy Taylor. "We're
creating the business roadmap -- through improved markets and
creative new business models -- that will lead industry to those
much-needed solutions."

About BIO Ventures for Global Health

BIO Ventures for Global Health (BVGH) is a global, non-profit entity
that seeks to break traditional barriers to global health product
development, bridging the gap between biotechnology's immense
promise and the enormous unmet health needs of the developing world.
By uncovering and building new market opportunities -- through
better market information, creative business models and new market
incentives -- BVGH aims to catalyze industry investment in global
health innovations to address the unmet health needs of the poorest
regions of the world. More information is online at
http://www.bvgh.org.

---------------------------------------------------------------------
-----------
Source: BIO Ventures for Global Health; Biotechnology Industry
Organization

http://www.arizonabiotech.com/
http://smsac.blogspot.com/
http://groups.yahoo.com/group/biotech-news/

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Phoenix Biocluster - Arizona Biocluster

Arizona Biocluster

Phoenix Biocluster Seeks Business & Research Opportunities
March 28 , 2005 by Editor

The city of Phoenix has officially become the nation's newest biotech cluster with the grand opening of its Downtown Biomedical Center and worldwide headquarters for TGen (Translational Genomics Institute) and IGC (International Genomics Consortium).

The city of Phoenix and State of Arizona have invested and laid the foundation for becoming one of the industry's foremost research centers with regards to neurogenomics and related research areas of Alzheimer's, autism, cancer, and diabetes. The city seeks to attract biotech and related companies to Phoenix, Arizona from Austin, Texas for business opportunities in Research and Development (R&D), collaboration, partnering and office expansion.

The Phoenix Biomedical Center provides a unique, urban environment for cutting edge companies to expand offices or open R&D centers. The $46 million dollar TGen/IGC building forms the foundation of the PBC, a 28-acre development area planned near the epicenter of Copper Square – a thriving and rejuvenated section of Phoenix featuring sports, music, theatre, restaurants and other entertainment and cultural venues. The futuristic, 173,000 square foot TGen/IGC building is owned by the City of Phoenix.

"Building our biotech industry is very important for the state's future economic growth and will benefit all its citizens," said Arizona Governor Janet Napolitano. "We are committed to investing resources, and fostering a positive investment climate in partnership with our universities, to make Arizona more attractive to out of state companies wishing to open or expand offices here."

"Now that we've completely moved into our state of the art facility, I'm looking forward to the next stages and milestones we will accomplish in the scientific community,” says Dr. Jeffrey M. Trent, TGen's President and Scientific Director. “The research conducted here will be valuable to companies and organizations worldwide.”

In addition to our rich cultural and entertainment venues, Downtown Phoenix has the resources and infrastructure necessary to attract and sustain world-class organizations and companies, said Phil Gordon, Mayor of Phoenix. “We're excited to have TGen, IGC, and NIDDK in our midst, and we invite biotech companies from out of state and around the world to investigate the business opportunities for R&D, collaboration, and expansion that we offer.”

A ribbon-cutting ceremony attended by Arizona State Governor, Janet Napolitano, Phoenix Mayor, Phil Gordon, U.S. Senator, Jon Kyl and TGen President & Scientific Director, Dr. Jeffrey M. Trent. The keynote speech was delivered by Francis S. Collins, M.D., Ph.D. Director, National Human Genome Research Institute. Thousands attended the celebration which also included a Health & Research Fair from 7:30 a.m. – noon with exhibits from more than 40 biotech and related partner organizations.

About the Phoenix Biomedical Center

The PBC is the keystone of the state-wide bioscience initiative and is expected to have a significant impact on biomedical discoveries, the quality of health care for Arizona 's residents, and the expansion and diversification of the state's economy. Other planned developments for the PBC area include the Arizona Biomedical Collaborative (a three university teaching facility), a College of Medicine, a College of Pharmacy, and a College of Nursing.

Major Regional Biotech Organizations & Resources

Arizona Heart Institute
Arizona State University
Banner Health
Barrow Neurological Institute
Mayo Clinic
NIDDK
Scottsdale Healthcare
St. Joseph 's Hospital
The Biodesign Institute of ASU
University of Arizona
Phoenix Region Facts

Population: 3.4 million
Bio-Related Companies: 1,000+
Major Airport : 23 major airlines, 7th busiest airport in the world
Higher Education: 25 institutions of higher learning, 277,000 enrolled students
Weather: Average temperature 73F. 300+ sunny days a year
Entertainment: 52 theatres, 40 museums, 200 art galleries, 4 pro sports teams

About TGen

The mission of the Translational Genomics Research Institute (TGen) is to make and translate genomic discoveries into advances in human health. Translational genomics research is a relatively new field employing innovative advances arising from the Human Genome Project and applying them to the development of diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases. TGen is focused on personalized medicine and plans to accomplish its goals through robust and disease-focused research programs and its state-of-the-art bioinformatics and computational biology facilities. For more information, visit the Web site: www.tgen.org.

About Phoenix

Phoenix is one of the fastest-growing cities in the nation. The region offers a growing and skilled workforce, a competitive business environment, easy access to major markets and more. The city has a wealth of programs and activities to assist businesses, large and small. Phoenix offers just about everything in the way of sports, recreation, arts, culture, dining, lodging and financial opportunities. Because of our beautiful weather, activities can be enjoyed year-round.

The city has won many major awards, including the Carl Bertelsmann Prize, a prestigious international competition that recognizes the best-run city government in the world. For more information about Phoenix and regional biotech related business opportunities, visit the Web site http://phoenix.gov or call 1-866-TECH CITY (832-4248) or (602) 534-6122.

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] for research/job in biotech.

i am pooja from India and would like to join as
project fellow in biotech.or wanna join job in research field.
i did M.Sc-biotech with first div.
kindly,help me if you can?
pooja

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Monday, June 20, 2005

[ biotech news ] MilkenInstitute.Org > Publications > The Greater Philadelphia Life Sciences Clus

http://www.milkeninstitute.org/publications/publications.taf?
function=Þtail&ID=E4&cat==ResRep

MilkenInstitute.Org > Publications > The Greater Philadelphia Life
Sciences Cluster: An Economic and Comparative Assessment

The Greater Philadelphia Life Sciences Cluster: An Economic and
Comparative Assessment
Ross DeVol, Rob Koepp, Lorna Wallace, Armen Bedroussian and Daniela
Murphy
June 2005

Price:$ 35.00*

As you order, the number of items in your shopping cart will appear
in the upper right corner. You may make changes at checkout.

The life sciences industry is an emerging powerhouse for U.S. global
economic competitiveness in the 21st century. So which metropolitan
areas are in the lead for this important engine of economic growth?

According to this study, Boston, the San Francisco Bay Area and
Greater Philadelphia have the most dynamic life sciences clusters in
the country.

Encompassing biotechnology, pharmaceuticals, medical devices,
associated research and development activities, and supporting
infrastructure including research universities, teaching
hospitals, medical laboratories and venture capital firms life
sciences is one of the most knowledge-intensive and research-rich
sectors of the U.S. economy. It directly and indirectly supports
millions of jobs and pays above-average wages to life science
industry workers.

The study was sponsored by BioAdvance, PricewaterhouseCoopers,
Pennsylvania BIO and the Greater Philadelphia Chamber of Commerce's
CEO Council for Growth, which asked the Institute to undertake the
study to gauge the Greater Philadelphia region's standing compared
to the other leading life sciences clusters in the U.S.

Researchers benchmark and assess the current position of the Greater
Philadelphia life sciences sector relative to 10 other leading
centers Greater New York, Boston, Greater Raleigh Durham,
Minneapolis, Chicago, Dallas, Greater San Francisco, Seattle,
Greater Los Angeles and San Diego and estimate the total impact on
the region's economy by calculating the multiple ripple effects,
evaluate how it is positioned for future growth by investigating its
ongoing ability to innovate, and formulate an overall composite for
the life sciences.

The Greater Philadelphia life sciences cluster ranks among the elite
centers in the country. Its life sciences industry is a clear
potential source of comparative advantage for the region's economy
over the long term and it ranks among the largest clusters in the
country.

The study includes detailed statistics from the dozens of
measurements examined by researchers in each of the 11 clusters

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Viventia to present at the BIO 2005 Forum

Viventia to present at the BIO 2005 Forum
TSX: VBI

TORONTO, June 20

Viventia Biotech Inc. (TSX: VBI - News) today announced that Nick Glover, President and Chief Operating Officer, will be presenting at the BIO 2005 Business Forum in Philadelphia on Wednesday, June 22nd, 2005.

WHEN: Wednesday, June 22nd, 2005 at 10:45 am EDT

WHERE: Pennsylvania Convention Centre, Room "D"
1101 Arch Street
Philadelphia, PA

About BIO 2005
BIO 2005 is the world's largest biotechnology gathering. This year, BIO will host a record number of high ranking international dignitaries leading national delegations from more than 60 countries. More than 18,000 biotech executives, investors, journalists, policy makers and scientists from more than 60 countries are expected to attend. For more information, please visit www.bio.org.

About Viventia Biotech

Viventia Biotech Inc. (TSX:VBI - News) is a biopharmaceutical company developing Armed Antibodies(TM), powerful and precise anti-cancer drugs designed to overcome various forms of cancer. Viventia's lead product is Proxinium(TM), which combines a cytotoxic protein payload significantly more powerful than traditional chemotherapies with the highly precise tumour-targeting characteristics of a monoclonal antibody. Proxinium(TM) is in clinical development for the treatment of head and neck cancer and bladder cancer, and is expected to enter advanced clinical trials in 2005.

This press release contains forward-looking statements, which are subject to risks and uncertainties inherent to the process of developing and commercializing human therapeutic products. Actual results could differ materially from those projected in this release. Certain statements included in this press release constitute forward looking statements. When used in this press release, the words "anticipate", "believe", "plan", "estimate", "expect", "intend", "will", "may", "should" and similar expressions, as they relate to us or our management, are intended to identify forward-looking statements. These forward-looking statements are not historical facts but reflect our current expectations concerning future results and events. These statements include, without limitation, statements with respect to the clinical and developmental timelines associated with Proxinium.

The Toronto Stock Exchange has neither approved nor disapproved
the information contained herein.

--------------------------------------------------------------------------------
Source: Viventia Biotech Inc.

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Sunday, June 19, 2005

[ biotech news ] Kreatech Biotechnology Launches a Series of ULS arrayCGH Labeling Kits Array Bas

Kreatech Biotechnology Launches a Series of ULS arrayCGH Labeling
Kits Array Based Comparative Genomic Hybridization (CGH) Analysis

AMSTERDAM,

New "ULS(TM) arrayCGH Labeling Kits" for Direct, Non-enzymatic
labeling of genomic DNA for microarray based comparative genomic
hybridization (arrayCGH) analysis

Kreatech Biotechnology BV announces the launch of a series of ULS
arrayCGH labeling kits offering its' proprietary ULS labeling
molecule bound to a choice of fluorescent dye pairs that have been
licensed by Kreatech including dyes from GE Healthcare/Amersham
(CyDyes), Perkin Elmer (Cyanine Dyes) and Dyomics (DYDyes). The
complete labeling kits include unique purification columns
(KREApure), blocking buffer (KREAblock) and hybridization buffers.

The ULS labeling of nucleic acids is a robust, one-step
procedure that is completed within 30 minutes. "The possibility of
analyzing genomic DNA directly without the need to amplify is a very
attractive feature to many researchers, not only does it save time
but it also removes the potentially biasing enzymatic step that is
currently required in order to label genomic samples" according to
Ted van der Lende, Director of product development.

The Universal Linkage System - ULS(TM) - is a proprietary
labeling technology that has been optimized for arrayCGH analysis on
DNA arrays. The ULS arrayCGH labeling kit has the unique feature of
allowing the user to label genomic DNA directly in a one step
labeling reaction (30 minutes), avoiding the need for a potentially
biasing enzymatic step. This results in more accurate data as well
as saving time and money. The ULS labeling efficiency is independent
of fragment length making it ideal for use with archival DNA. Where
samples are limiting and amplification is required, this is carried
out using natural unmodified nucleotides which is then followed by
the one step ULS labeling.

Brent Keller, acting Commercial Director for Kreatech states "Our
decision to make available arrayCGH labeling kits that offers a
choice of fluorescent dye pairs from the leading dye manufacturers
is consistent with our strategy to offer ULS technology independent
of array platform used and the labels that researchers work with. In
this way, ULS can be the ubiquitous choice of researchers for their
labeling needs, eliminating the concern over matching arrays and
labels with the offering of every manufacturer."

Kreatech earlier this year launched a line of aRNA labeling kits
for expression arrays with dye pairs from GE Healthcare, Perkin
Elmer, Dyomics and a Biotin system for Affymetrix users.

For more information on the ULS labeling kits visit
http://www.kreatech.com

SOURCE Kreatech Biotechnology B.V.

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Generex Biotechnology Presents Oral-lyn(TM) Clinical Trial Results

Generex Biotechnology Presents Oral-lyn(TM) Clinical Trial Results

Company presents at the American Diabetes Association 65th
Scientific Sessions

TORONTO,

Generex Biotechnology Corporation (Nasdaq: GNBT - News), a leader in
the area of buccal drug delivery, today announced clinical trial
results in respect of Oral-lyn(TM), the Company's proprietary oral
insulin buccal spray formulation, presented at the 65th Annual
Meeting & Scientific Sessions of the American Diabetes Association
held June 10 - 14, 2005 in San Diego.

Generex clinician Dr. Jaime Guevara-Aguirre presented a poster in
the Clinical Therapeutics/New Technology -- Insulin Delivery Systems
category titled "A Series of Open-Label Studies Comparing Various
Formulations of Oral-lyn(TM) Propellant Spray in Patients with Type-
1 Diabetes Mellitus" (co-authored with M. Guevara and J. Saavedra).

During the normal drug development process and besides evaluating
Oral-lyn(TM) against its active comparator, it was necessary to test
preparations with different insulin concentrations or different
ratios of the excipients included in the Oral-lyn(TM) formulation.
In Dr. Guevara's study, the glucodyanmic (GD) profiles induced by
single pre-prandial versus pre- and post-prandial split doses of
Oral-lyn(TM) were compared to the GD profile of Humulin-R in a 3-day
(4 hours per day) open-label study performed in patients with Type-1
diabetes. In a second experiment, Dr. Guevara tested the relative
efficacy of various Oral-lyn(TM) preparations in a series of similar
4-hour open label studies performed in the same individuals with a
view to determining the most appropriate Oral-lyn(TM) preparation
for longer term trials.

In the first experiment, Oral-lyn(TM), in either a single pre-
prandial dose or in a split-dose fashion, was administered to 6
patients with Type-1 diabetes. The corresponding GD profiles were
compared to the GD profiles induced by the administration of the
active comparator (subcutaneous injection of Humlin-R) 30 minutes
prior to the same test meal. The study determined that a pre- and
post-prandial split-dose of Oral-lyn(TM) was better than a pre-
prandial single dose and comparable to the GD profile induced by
Humulin-R.

The second experiment included a series of open-label studies at
which the same 6 patients with Type-1 diabetes received, in
different days, single does of each preparation of Oral-lyn(TM) in a
split-dose regimen with 5 puffs before and 5 puffs after the test
meal. After evaluation of the GD profiles of the various
preparations, Dr. Guevara was able to identify the preparation that
exhibited the best GD profile for use in longer term trials.

In addition, Generex clinician Professor Itamar Raz published a
paper in the Abstract Book for the 65th Annual Scientific Sessions
titled "Addition of Oral-lyn(TM) at Mealtimes in Subjects with Type-
2 Diabetes Maintained on Glargine + Meformin -- A Comparison with
Placebo" (co-authored with A. Dubinsky, M. Kidron and J. Wainstein).

The purpose of the Professor Raz study was to determine the
metabolic effect of Oral-lyn(TM) at mealtime on a long-term basis
(12 weeks) in patients with Type-2 diabetes maintained on once-a-day
subcutaneous Glargine insulin injection therapy at bedtime and
Metformin. The primary hypothesis was that Oral-lyn(TM) can be used
safely at mealtimes and will improve 7 point glucose profiles,
fructosamine and the baseline HbA1c levels 12 weeks after treatment.

This was a randomized, double-blind, long-term (12 weeks) study in
26 patients with Type-2 diabetes (male or female) with poorly
controlled blood glucose maintained on once a day s.c. Glargine and
Metformin. After the initial screening visit, subjects maintained
their regular treatment for two weeks as a run-in period. Following
the training of the Oral-lyn(TM) device operation and dosing
schedules, they were divided into two groups. One group had 7 puffs
of Oral-lyn(TM) TID, and the other group had 7 puffs of placebo TID.
Both groups took the puffs 10 minutes before mealtime in addition to
their regular treatment. In cases where self-glucose values were
above 12mmol/L before any meal or before bedtime, an additional 7
puffs were added. Each subject had routine blood chemistry and HbA1c
as well as fructosamine levels at the beginning of the study and at
the end of every month during the study period. Beginning with the
initial screening visit, each subject had to monitor his/her blood
glucose at least three times a day and once a week for a 7-point
profile.

The interim results, after 8 weeks of treatment, showed no change in
fasting glucose while in post-prandial glucose there was a 15.4%
reduction in the Oral-lyn(TM) group versus 3.9% elevation in the
placebo group. Furthermore, the study found a reduction of
fructosamine in the Oral-lyn(TM) group of 6.4% versus 3.6% in the
placebo group and for HbA1c there was a 6.6% reduction in the Oral-
lyn(TM) group versus 3.4% in the placebo group. The effective post-
prandial trend can be seen clearly, although the results are not
statistically significant. This may be partially due to the short
time period and small sample size of the study.

The study concluded that in patients with Type-2 diabetes maintained
on Glargine and Metformin, Oral-lyn(TM) was especially effective in
controlling post-prandial glucose excursions.

About Generex

Generex (http://www.generex.com) is engaged in the research and
development of drug delivery systems and technologies. Generex has
developed a proprietary platform technology for the delivery of
drugs into the human body through the oral cavity (with no deposit
in the lungs). The Company's proprietary liquid formulations allow
drugs typically administered by injection to be absorbed into the
body by the lining of the inner mouth using the Company's
proprietary RapidMist(TM) device. The Company's flagship product,
oral insulin (Oral-lyn(TM)), is in late stage clinical trials around
the world.

Safe Harbor Statement: This release and oral statements made from
time to time by Generex representatives concerning the same subject
matter may contain "forward- looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. These
statements can be identified by introductory words such
as "expects," "plans," "intends," "believes," "will," "estimates," "f
orecasts," "projects" or words of similar meaning, and by the fact
that they do not relate strictly to historical or current facts.
Forward- looking statements frequently are used in discussing
potential product applications, potential collaborations, product
development activities, clinical studies, regulatory submissions and
approvals, and similar operating matters. Many factors may cause
actual results to differ from forward-looking statements, including
inaccurate assumptions and a broad variety of risks and
uncertainties, some of which are known and others of which are not.
Known risks and uncertainties include those identified from time to
time in the reports filed by Generex with the Securities and
Exchange Commission, which should be considered together with any
forward-looking statement. No forward- looking statement is a
guarantee of future results or events, and one should avoid placing
undue reliance on such statements. Generex undertakes no obligation
to update publicly any forward-looking statements, whether as a
result of new information, future events or otherwise. Generex
cannot be sure when or if it will be permitted by regulatory
agencies to undertake additional clinical trials or to commence any
particular phase of clinical trials. Because of this, statements
regarding the expected timing of clinical trials cannot be regarded
as actual predictions of when Generex will obtain regulatory
approval for any "phase" of clinical trials. Generex claims the
protection of the safe harbor for forward-looking statements that is
contained in the Private Securities Litigation Reform Act.

---------------------------------------------------------------------
-----------
Source: Generex Biotechnology Corporation

Biotech News
Arizona Biotech
Entrepreneurs
High Tech

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] More than 45 Delegates from the New Zealand Biotechnology Industry Highlight New

More than 45 Delegates from the New Zealand Biotechnology Industry
Highlight New Zealand Innovation and Global Connectedness at BIO
2005

BIO 2005 Annual Convention

Over 150 Years of Life Sciences R&D Has Produced a Rapidly Growing
Biotech Industry Addressed to Health and Wellness, Industrial
Biotech, Agriculture, Forestry and More

More than 150 years of life sciences research and technological
innovation, combined with strong global partnerships, and a public-
private collaborative approach to business have given New Zealand
one of the world's fastest growing biotechnology industries. Today
New Zealand biotechnology applications range beyond agriculture to
add medicine, human health, wellness and performance, industrial
biotechnology, forestry, biosecurity, and environmental
applications.

To promote awareness of New Zealand's growing global presence in
biotechnology, the Honorable Pete Hodgson, New Zealand Minister of
Commerce and ex-Minister of Research, Science and Technology will
lead a delegation of 47 companies and organizations to the BIO 2005
conference, taking place in Philadelphia, PA from June 19 - 22.
Through its internationally oriented biotechnology industry and its
presence at BIO 2005, New Zealand is reaching out to partner with
leading U.S. and international research institutions and
universities, companies, and state agencies.

New Zealand Pavilion

The New Zealand Government's economic development agency New Zealand
Trade and Enterprise (NZTE) will host a pavilion in the BIO 2005
Exhibition Hall. The pavilion will showcase a variety of New Zealand
research initiatives and companies in the areas of human medicine,
health and wellness, agricultural biotechnology, industrial
biotechnology and support organizations. The pavilion will include a
meeting area for networking and one-on-one meetings during the
conference. NZTE will co-host with the Australian Pavilion a special
exhibit hall event on Tuesday June 21, 2:00 - 4:00 pm, featuring
fine wines from New Zealand and Australia. The New Zealand Pavilion
is located in Hall C, Stands 749-856.

New Zealand Country Seminar

On Sunday June 19, International Day presenters for New Zealand will
include Minister Hodgson, along with Chris Boalch, Director of
Biotechnology, NZTE; Richard Furneux, Ph.D., CEO of GlycoSyn, an
Industrial Research Ltd company focused on glycobiology; Larry
Ellingson, CEO of Protemix USA, a New Zealand founded
biopharmaceutical company; and Howard Moore, Executive Director of
the recently founded venture firm, BioPacificVentures. Together they
will provide an overview of the New Zealand biotech industry and
business environment, including government initiatives planned to
grow the industry, as well as the New Zealand industry's expanding
international linkages.

The New Zealand Minister of Commerce, Hon. Pete Hodgson, said, "Much
of New Zealand's wealth has been built on a proven ability to add
value to natural resources by applying biological knowledge. Now
unique approaches to biotechnology pioneered in New Zealand are set
to have a major impact on the way we all deal with health and
environmental issues.

"The New Zealand biotech sector has firm backing from the New
Zealand Government which recognises its importance to the economy.
It is working with the New Zealand biotechnology community to
implement a detailed strategy to put in place the necessary
infrastructure to promote success on a global scale."

New Zealand Companies at BIO2005

Representatives of some of New Zealand's leading biotechnology
companies, as well as scientists from cutting edge research programs
at the country's Crown Research Institutes and Universities, will
represent the nation's outstanding capabilities and global research
at BIO2005. Just a few of the New Zealand companies represented at
BIO include:

-- Proacta and Protemix are two companies that illustrate well the
global connectedness of New Zealand biotechnology. Taking advantage
of New Zealand innovation, scientific know-how and low cost of
research, these two companies are among those who have expanded
operations to the United States for access to larger patient
populations and markets. Proacta is developing treatments for cancer
that take advantage of the oxygen-poor environment in tumors.
Protemix is engaged in the development of a novel treatment to
repair heart damage in patients with diabetes, as well as other
therapies for cardiovascular disease, diabetes and other metabolic
conditions.

-- Lactopharma and Ovita are two companies whose research
demonstrates New Zealand's ability to mine leading agricultural
research for new human therapeutic applications. Lactopharma is
developing applications of lactoferrin, a milk-derived protein with
both anti-inflammatory properties and the ability to promote bone
formation and inhibit bone absorption. Ovita's research on muscle
development and twinning in sheep offers opportunities for
development new treatments against muscle wasting and to aid
fertility in humans.

-- Pacific Edge Biotechnology Ltd, a biomedical company with a
strategic focus on "human health and wellness" combines state-of-the-
art molecular biology and micro array technology with world-class
tissue banks and clinical data. These resources, combined with
proprietary analytical software, enable the company to identify
unique gene signatures of disease.

-- IRL - With a focus on creating new technologies, Industrial
Research Ltd (IRL) draws from New Zealand science & technology
platforms to create globally competitive products for customers
worldwide. This focus includes a core emphasis within biotechnology.
For example, one of IRL's key business units, GlycoSyn, is drawing
from world-class expertise in carbohydrate chemistry to collaborate
with Albert Einstein College of Medicine in New York. This
partnership has enabled them to produce novel treatments for cancer
and autoimmune diseases that have led to further clinical
development with companies in the United States and Australia. A
separate spin-out company from Industrial Research, IRL Biopharm,
manufactures many of the potent molecules used as "warheads" in
anticancer antibodies under development by a major US biotech
company.

-- Neuren Pharmaceuticals is a biopharmaceutical company whose
product pipeline is applicable to two of the world's largest and
fastest growing therapeutic markets: neuroprotection and metabolism.
The company has many U.S. and other global collaborations, including
one with Walter Reed Army Institute of Research focused on
neuroprotectant treatments and traumatic brain injury.

For more information on New Zealand and its biotechnology industry,
as well as its participation in BIO 2005, please visit
www.nzte.govt.nz/bio2005.

Arizona Biotech News
Arizona Biotech News
Famous Entrepreneurs
Arizona Tech

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Science & Biotechnology Combine to Unite Jerusalem

Science & Biotechnology Combine to Unite Jerusalem

Atlanta, GA, May 10, 2005
A conference scheduled for June 26-28 of this year will unite minds on both sides of the wall in Jerusalem. The conference, entitled “Basal Ganglia, Dopamine and Learning: Integrating Computational and Clinical Perspectives,” is a meeting of top neuroscientists from Europe, North America and the Middle East. This meeting is important for Science and Medicine as well as for Israel, as part of the event will held in Palestinian Jerusalem and part in Israeli Jerusalem.

One of the key sponsors of the event is an American-Israeli biotechnology company, Alpha Omega. Imad Younis, President of the Alpha Omega companies says “We are proud to sponsor part of this event as it gives an example to the people on both sides of the wall that we can learn together, work together and also live together.”

The ethnic makeup of Alpha Omega itself is a powerful example of unity. The company employs Palestinians and Jews, Muslims and Christians from various countries. Alpha Omega was originally founded in Israel but has now expanded to the United States and Germany. Imad and his family currently live in the US but plan to relocate back to Israel. According to Imad, “this event is significant as it gives a small push towards the Middle East in which I and my children wish to live.”

The meeting will host a great panel of speakers from the international neuroscience community. The focus of the discussions, the “basal ganglia,” is a region of the brain that plays a critical role in the pathogenesis of movement disorders like Parkinson’s Disease, Huntington’s disease and dyskinesia. Recent studies have indicated the involvement of the basal ganglia in everyday complex behaviors that require coordination between cognition, motivation and movements.

The researchers study the basal ganglia in normal behavior as well as in movement disorder behaviors in an effort to discover how the activity in the structure differs in the two scenarios. “Our belief is that only through such broad and interdisciplinary understanding will we be able to provide better methods for diagnosis, follow-up and therapy of these common devastating human diseases” says Dr. Hagai Bergman of The Hebrew University Faculty of Medicine in Israel.

The format for the meeting is designed to encourage discussion between attendees and it is open to anyone who wishes to attend. The conference is organized by Dr. Bergman and Dr. Mark Gluck of the Newark Neuroscience Center at Rutgers University. The convention will take place at the Konrad Adenauer conference Center, Mishkenot-Sha'ananim, in the beautiful Yemin Moshe quarter of Jerusalem. During the conference, attendees will take a bus to Al Quds Medical School for one of the sessions.

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Wednesday, June 15, 2005

[ biotech news ] Biotechnology Laboratory Technician Certificate

Biotechnology Laboratory Technician Certificate
http://www.csusm-es.org/biotech/

CSUSM - Extended Studies - Biotechnology Laboratory Technician
Certificate Program

Train for a New Career in Biotechnology! Program begins January 18,
2005.

National and local trends indicate that there is a promising
employment picture for individuals with specific training in
biotechnology. While biotech-related jobs in 2003 jumped more than
12.4% over the previous year, it is projected that the San Diego
biotech workforce will grow on a faster-than-average basis (17.5%)
for this decade (San Diego Economic Bulletin, December 2003 and
Nature, December 11, 2003). Inherent in this workforce growth is the
increasing need for qualified laboratory technicians.

This specialized Biotechnology Laboratory Technician Certificate
program is designed to:

Provide students with a foundation in the knowledge and techniques
needed to earn entry-level positions as lab technicians in the
growing biotechnology field
Train laboratory personnel for careers and jobs as laboratory
technicians and/or research assistants
Concentrate on the laboratory techniques most commonly used by firms
in their research,manufacturing, and quality control laboratories
Provide industry employers with a workforce-ready pool of well-
trained lab technicians, Quality Assurance and research /
manufacturing assistant

This program provides an overview of the industry and the functions
of biotechnology and pharmaceutical laboratories in research,
manufacturing and quality control. Emphasis on the industry, the
role of biotechnology companies and the process of discovery and
development of new products. Also covered are federal regulations
with emphasis on Good Laboratory Practices (GLP) and Good
Manufacturing Practices (GMP).

The 17-semester unit certificate can be completed in one full year,
provided necessary prerequisites
have been completed. Courses are drawn from the regular Cal State
San Marcos catalog and include:

BIOL 359 Biotech/Pharmaceutical Industry Labs (3 units)
BIOL 355 Molecular Biotechnology (4 units)
BIOL 356 Cellular Biotechnology (4 units)
CHEM 351 Biochemistry (3 units)
BIOL 358 Computer Skills for Biotechnology (3 units)
****Biotech/Pharma Industry Laboratories (BIOL 359)

This exciting new course will provide you with a comprehensive
overview of the industry and the functions of biotechnology and
pharmaceutical laboratories in research, manufacturing and quality
control. Emphasis is on the industry, the role of biotechnology
companies and the process of discovering and developing new
products. Also covered are federal regulations with emphases on Good
Laboratory Practices (GLP) and Good Manufacturing Practices
(GMP).This course may be taken as a "stand alone" course for
individuals who simply want an introduction to the biotech/pharma
industry, or as the first course in the Biotechnology Laboratory
Technician Certificate of Competence. No prerequisites; no program
application required. May be used as an elective for the CSUSM
biology degree.

Course No: BIOL 359
Fee: $600
Dates: Tuesdays, January 18 April 5
Saturdays, January 22 and April 16
Times: 5:30 am - 8:30 pm (Tuesdays) and 8:30-3:00 pm (Saturdays)
Units: Three Semester Units (degree applicable)
Location: Please call the Extended Studies office at (760) 750-4020
for classroom location.
Facilitator: Al Kern, Director of Biotechnology, Cal State San
Marcos
Instructors: Program features a wide variety of industry leaders and
content experts.

For more information on the certificate program and to receive an
application packet, contact Extended Studies at (760) 750-4020.

Arizona Biotech
Biotech News
Pigeon Forge Cabins
SMS.ac

Biotech News 0 comments

Arizona Biotech

HARRISBURG, Pa., June 13

Pennsylvania Department of Community and Economic Development (DCED)
Secretary Dennis Yablonsky today announced Governor's Action Team
(GAT) projects for five Biosciences companies that were offered
approximately $5 million in state assistance to create and retain
nearly 500 jobs in Pennsylvania.

"The bioscience industry is transforming the commonwealth's economy
by supporting new companies, creating jobs and contributing to
community growth," Yablonsky said. "Today's announcements
demonstrate the commonwealth's commitment and tradition to
innovation through our forward thinking and dedication to the life
sciences industry. Projects like these ensure our continued growth
and success in this constantly evolving industry throughout
Pennsylvania and beyond."

Yablonsky announced the following GAT projects:

Agentase LLC is expanding its Allegheny County operations by
relocating to a new facility in Harmar Township. The chemical
engineering company completed the Research & Development (R&D) phase
for its new products and needs to relocate to a facility with wet
chemistry lab space. At least 54 jobs will be created within three
years and 22 existing employees will be retained. The Governor's
Action Team (GAT), economic development professionals who report
directly to Gov. Edward G. Rendell and Yablonsky, and the Allegheny
County Department of Economic Development worked with Agentase on
this project. DCED offered the company a $328,300 funding package
that includes: a $200,000 Small Business First (SBF) loan; a $50,000
Opportunity Grant; $24,300 in Job Training Assistance (JTA); and
$54,000 in Job Creation Tax Credits (JCTC). Agentase is focused on
the development and implementation of biocatalysts. Its products
include anti-chemical warfare/terrorism sensors and pesticide
remediation.

Charles River Laboratories has outgrown its current Exton facility
and plans to relocate to a new 60,000-80,000-square-foot facility in
southeastern Pennsylvania. A location has not yet been determined.
The company, a provider of solutions that advance the drug discovery
and development process, will create at least 36 jobs within three
years and retain 92 existing employees. DCED offered the company a
$1.08 million financial package that includes: $450,000 Machinery
and Equipment Loan Fund (MELF); $300,000 Opportunity Grant; $150,000
JTA; and $180,000 JCTC. Charles River Laboratories' products and
services are designed to enable its clients to bring drugs to market
faster and more efficiently.

Integrated BioSciences Inc. (IBS) is expanding its existing
Lewisberry, York County facilities and infrastructure by purchasing
additional equipment and hiring new employees. At least 65 jobs will
be created within three years and the company, which is a complete
contract manufacturer of medical devices, automated equipment
and "box build" electronics, will retain 22 existing employees. DCED
offered the company a $705,000 funding package that includes: a
$500,000 loan through MELF; a $75,000 Opportunity Grant; and
$130,000 JCTC. IBS is an FDA registered, ISO 9001:2000 certified
manufacturer that offers total project management for class I and II
medical devices for companies looking to outsource the manufacture
of their products, automated equipment or entire manufacturing
programs.

Isolagen Inc. has expanded operations by relocating its Texas
headquarters and R&D to its existing Exton, Chester County,
facility. The company, which specializes in the development and
commercialization of cellular therapies for soft and hard tissue
regeneration, will create at least 140 new jobs within three years.
DCED offered Isolagen a $1.7 million financial package that
includes: a $500,000 loan through MELF: a $400,000 Opportunity
Grant; $100,000 JTA; and $700,000 JCTC. The company's technology
process has potential applications in cosmetic dermatology, cosmetic
surgery, periodontal disease, reconstructive dentistry and other
therapies. Isolagen has five secured patents and five additional
patents pending.

NanoDynamics Inc. has four existing business units and is creating a
new division in the City of Pittsburgh - ND Life - in collaboration
with the McGowan Institute of Regenerative Tissue. At least 50 jobs
will be created by the company, which will leverage existing
expertise in nanotechnology-based products to address needs and
opportunities in the life sciences marketplace. DCED offered
NanoDynamics a $1.15 million funding package that includes: a
$500,000 loan through MELF; a $200,000 loan through SBF; a $200,000
Opportunity Grant; $100,000 JTA; and $150,000 JCTC. NanoDynamics is
a leading manufacturer of nanomaterials to improve the form,
function and performance of industrial and consumer products. The
new division is located in the Pittsburgh Life Sciences Greenhouse.

"Today's announcements further demonstrate the commonwealth's
leadership in supporting this important industry," said Fritz
Bittenbender, president of Pennsylvania Bio, the state biosciences
trade association. "From tradable R&D tax credits, to the Life
Sciences Greenhouse Initiative, venture capital programs and more,
Pennsylvania has created an environment that helps grow and sustain
bioscience companies. With the continued support of the governor and
the legislature, Pennsylvania will be a global leader in the
biosciences."

BIO International handpicked the commonwealth as the 2005 host state
for the BIO 2005 Annual Conference, taking place June 19-22 in
Philadelphia.

For information on DCED funding, visit http://www.newpa.com. For
additional information on Pennsylvania Bio, visit
http://www.pennsylvaniabio.com.

For information on each of the five companies announced today, visit
the following websites: http://www.agentase.com;
http://www.criver.com; http://www.ibiosci.com;
http://www.isolagen.com; http://www.nanodynamics.com.

CONTACT: Penny Kline, Pennsylvania Department of Community and
Economic Development, +1-717-783-1132.

---------------------------------------------------------------------
-----------
Source: Pennsylvania Department of Community and Economic Development

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Biotech News 0 comments

Arizona Biotech

NEW YORK, June 13 -- The U.S. Supreme Court ruled today that the
pharmaceutical companies have a broad immunity from patent
infringement claims when they engage in research on promising new
drug candidates. In a unanimous opinion authored by Justice Antonin
Scalia, the Supreme Court held that the Federal Circuit had erred
when it drastically limited the protection of the FDA safe harbor,
applying it only to the late-stage testing on human patients.

"This was a grand slam homerun for patients and for drug innovators.
The Supreme Court gave drug companies and researchers enormous
latitude to conduct the testing necessary to bring promising
therapies to needy patients. It means that researchers will not have
to sit on their hands for a decade when they have discovered a
promising drug, but rather, without skipping a beat, can conduct the
experiments they need to conduct to make sure the drug gets to sick
patients as soon after patent expiration as possible."

-- E. Joshua Rosenkranz, Heller Ehrman LLP

The case, Merck KGaA v Inegra LifeSciences is the most significant
patent infringement ruling to confront the biotech and
pharmaceutical industries in a generation.

WHO: Attorney E. Joshua Rosenkranz
* Attorney E. Joshua Rosenkranz presented the oral argument, on
behalf of Merck KGaA, before the U.S. Supreme Court in April 2005.

http://groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Biotech Research Breakthroughs, Collaborations, and Economic Incentives

Biotech Research Breakthroughs, Collaborations, and Economic
Incentives to Be Announced at BIO 2005

A number of state and international economic development agencies
and private companies will make announcements to the press at a
special venue during the BIO 2005 Annual International Convention,
June 19-22 at the Pennsylvania Convention Center in Philadelphia.

The press conferences will spotlight scientific advancements, new
research agreements, and biotech business opportunities around the
world. The schedule of press conferences, listed in chronological
order, includes the following:

* Government of India -- Recent Policy Developments
Will Make India a Hotbed for Biotech
Kapil Sibal, Indian Minister for Science & Technology,
Amar Singh, Member of Parliament, and others will
outline why India is fast emerging as a significant
biotechnology hotbed in the Asia-Pacific region.
Sunday, June 19 at 10:00 am, Room 203B
Contact: Kapil Sibal, 24 64 1074

* Queensland, Australia -- Biotechnology Breakthroughs
The Honourable Peter Beattie, MP, Premier of
Queensland, will announce breakthroughs in research and
development within Queensland's biotechnology industry.
His announcement will highlight R&D funding
commitments, new industry partnerships, new research
collaborations, and significant policy decisions, such as the
Biodiscovery Bill.
Monday, June 20 at 9:00 am, Room 203B
Contact: Tina Radburn, (213) 346-0090,
tina.radburn@premiers.qld.gov.au

* BioAdvance -- Greater Philadelphia Life Sciences
Study Findings
BioAdvance will announce findings of a first-ever look at
the Greater Philadelphia area's competitive position within
the life sciences industry. BioAdvance will release a June
2005 Milken Institute study, titled "The Greater
Philadelphia Life Sciences Cluster: An Economic and
Competitive Assessment."
Monday, June 20 at 10:00 am, Room 203B
Contact: Ellen Semple, (215) 966-6207, esemple@bioadvance.com

* Victoria, Australia -- New Biomedical Announcements,
Plus Latest Results in the Kangaroo Genomics Project
Victoria Government Premier Steve Bracks, Treasurer
John Brumby and Minister for Health Bronwyn Pike will
deliver major biomedical announcements and the latest
results in kangaroo genomics research projects. Victoria is
partnering with the US NIH on sequencing the kangaroo genome.
Monday, June 20 at 10:00 am, Room 204A
Contact: Trish Vardon, +61 (0)3 9651 9236,
trish.vardon@iird.vic.gov.au

* British Columbia -- Hot Opportunities in North America
British Columbia Premier Gordon Campbell will announce
economic development incentives for the biotechnology
industry in Canada.
Monday, June 20 at 11:00 am, Room 203B
Contact: Linda Thorstad, (604) 761-5046,
lthorstad@leadingedge.ca

* Singapore -- The Biopolis of Asia
Singapore is dedicated to enhancing human healthcare as
one of the world's most preeminent life sciences hubs. The
Singapore Economic Development Board will emphasize
opportunities that currently exist in Singapore as a base for
R&D investment and as a strategic location for Biomedical
Sciences manufacturing.
Monday, June 20 at 12:00 pm, Room 203B
Contact: Daphne Teo, +65 6235 4495, teod@ruderfinnasia.com

* Invitrogen -- A New System for Disease Research
Invitrogen will announce new research technologies geared
toward specific disease models and pathways. Invitrogen
will introduce a system that ties its technologies together to
target applications and pathways.
Monday, June 20 at 2:00 pm, Room 203B
Contact: Gregory L. Geissman, (760) 476-7032,
gregory.geissman@invitrogen.com

* Wyeth & Dublin City University -- Collaboration on
Advanced Technologies for Protein Expression
Wyeth and Dublin City University have entered into a
collaborative research agreement, with funding support
from the Science Foundation of Ireland, to investigate gene
expression pathways of cultured mammalian cells relevant
to their industrial use in biopharmaceutical production. The
project will involve the use of genomics and proteomics
technologies in the identification of genes expressed in
Chinese hamster ovary cells that are important in
supporting outstanding cell growth and protein
productivity in production bioreactor cultures.
Tuesday, June 21 at 11:00 am, Room 203B
Contact: Gerald V. Burr, (484) 865-5138, burrg@wyeth.com

* Commonwealth of Massachusetts -- Joint Scientific
Research Collaborations between Massachusetts and
the Ministry Of Education, University, and Research of
the Italian Republic
Massachusetts Governor Mitt Romney will sign a
Memorandum of Understanding designed to further the
establishment of bilateral networks and partnerships and to
facilitate joint scientific, medical research and
biotechnology development projects in Massachusetts and
Italy.
Tuesday, June 21 at 1:00 pm, Room 203B
Contact: Amy Speer, (617) 788-3636, Amy.Speer@state.ma.us

* Biotechnology Industry Organization -- The Value of
Biotech Healthcare Therapies
Amit Sachdev, BIO's Executive Vice President, Health,
and Jayson Slotnick, BIO's Director, Medicare
Reimbursement & Economic Policy, will release the
results of a study on the value of biotech therapies.
Tuesday, June 21 at 2:00 pm, Room 203B
Contact: Jayson Slotnick, (202) 962-9200, jslotnick@bio.org

* Montgomery County, Md. -- Maryland Welcomes
Britain's Xceleron
Xceleron, the world's foremost company using the
nanotechnology of accelerator mass spectrometry in drug
development, will announce its new North American
Headquarters, to be located in Montgomery County,
Maryland. Xceleron's technologies have been proven to
speed drug development and reduce attrition rates.
Tuesday, June 21 at 3:00 pm, Room 203B
Contact: Joseph H. Shapiro, (240) 777-2000,
joseph.shapiro@montgomerycountymd.gov

* MDS Pharma Services -- Biomarker Alliance Launch
Dr. Jean W. Lee, Research Fellow, and Fred Pritchard,
vice president, Drug Development Programs, of MDS
Pharma Services will announce the formation of a
biomarker alliance among a coalition of commercial and
academic groups.
Wednesday, June 22 at 11:00 am, Room 203B
Contact: John F. Kouten, (908) 281-6099

[ biotech news ] Maryland Biotechnology Companies to Show Up in Force on the Biotechnology Industry Organization Show Floor

Maryland Biotechnology Companies to Show Up in Force on the
Biotechnology Industry Organization Show Floor

Maryland's biotechnology community has united and will turn out en masse at the Biotechnology Industry Organization's (BIO) 2005 Annual
International Convention in Philadelphia, June 19-22, 2005 at the
Pennsylvania Convention Center.

The Maryland Pavilion will have nearly 5,000 square feet of
exhibit space in Exhibit Hall C and feature 36 exhibitors at the
world's largest biotechnology event. More than 18,000 biotech
executives, investors, journalists, policy makers and scientists
from more than 60 countries are expected to attend the three-day
meeting.

The biotechnology community in Maryland, including the Tech
Council of Maryland, the Maryland Department of Business and
Economic Development, the Montgomery County Department of Economic
Development, and MDBio has helped elevate Maryland's vibrant family
of biotech companies by constructing one of the show's largest state
pavilions.

"The Maryland Pavilion will feature the broadest range of the
most progressive technologies anywhere on the Bio show floor," said
Edward M. Rudnic, Chairman, President and CEO of Advancis
Pharmaceuticals and Chair of the Tech Council of Maryland's
BioAlliance. "This pavilion has small, medium and large
biotechnology firms and will showcase why it is so important for
companies to move their operations or invest in Maryland
biotechnology," he said.

According to a recent study conducted by Pfizer, the
Biotechnology and Pharmaceutical industry created more than 33,000
new jobs in 2003 and contributed to an average salary range nearly
70 percent higher than the state average. The Pfizer survey also
demonstrated that the biotechnology and pharmaceutical industries
contributed nearly $146 million in income, sales and property taxes
to Maryland in 2003.

The Maryland Pavilion is located in Hall C of the Philadelphia
Convention Center in booths 124 through 344. Smaller pavilions from
Malaysia, Florida, and Minnesota flank the Maryland Pavilion.

We also encourage you to visit these progressive Maryland
biotechnology companies featured at the Maryland Pavilion:

Gene Logic Inc. -- Booths 242, 243, 143, and 145
Gene Logic's partnership-based philosophy has guided our
emergence as a leading provider of products and services across the
entire drug development value chain: drug discovery, pre-clinical,
and clinical. Our portfolio of offerings covers this spectrum with
capabilities in Genomics & Toxicogenomics, Preclinical Services,
Drug Repositioning & Selection, and Clinical Pharmacogenomics.
Contact: Jennifer R. Garms, JGarms@genelogic.com

Advanced Product Enterprises LLC -- Booths 242, 243, 143, and 145
Advanced Product Enterprises LLC is a Maryland based
biotechnology company involved in the identification, testing,
development, and sell of biomolecular products. Additionally,
Advanced Product Enterprises provides its expertise to the
scientific community via numerous scientific services that are
available to both government and privately funded investigators.
Contact: Joseph N. Garner, Ph.D., garner@ape-bio.com

Fort Detrick Business Development Office -- Booths 242, 243,
143, and 145 The Fort Detrick Business Development Office
enhances collaboration and business activity between Fort Detrick
and private industry. We serve, at no cost to the user, as a bridge
to opportunity for our customers by helping them make the right
connections, develop new business and initiate cooperative
research.
Contact: Darryl Rekemeyer, darryl.rekemeyer@fdbdo.com

A&G Pharmaceutical, Inc. -- Booths 242, 243, 143, and 145
Our Precision Antibody(TM) service rapidly develops customized,
high-affinity monoclonal antibodies to your target antigen in as
little as 30 days with a success rate over 90%.
Contact: Michael Keefe, mkeefe@agrx.net

Trophogen, Inc. -- Booths 242, 243, 143, and 145
Trophogen, Inc, was founded in 2001 by the management team and
inventors, Drs. Bruce Weintraub, Mariusz Szkudlinski, and Toucan
Capital. Trophogen's unique protein engineering platform technology
allows design of more potent and efficacious analogs of glycoprotein
hormones and related growth factors to address several large
therapeutic markets including infertility.
Contact: Bruce D. Weintraub M.D., bweintraub@trophogen.com

Protiveris, Inc. -- Booths 242, 243, 143, and 145
Protiveris Inc. is a nanotechnology company dedicated to the
commercialization of cantilever systems for research, drug
discovery, bio-defense and diagnostic applications. The VeriScan(TM)
3000 biosensor and nano-cantilever array chips deliver label-free,
real-time data that provides a unique, high value insight into the
binding interactions of cells, proteins, antibodies and drug
candidates.
Contact: Robert G. Menzi, rmenzi@protiveris.com

Kemp Biotechnologies, Inc. -- Booths 242, 243, 143, and 145
Kemp Biotechnologies, Inc. offers contract cell culture process
development and custom protein expression and purification. Kemp
has complete gene construct to batch record development capability.
Kemp's services are provided to large pharmaceutical,
biopharmaceutical and virtual companies to assist in all their
outsourcing needs.
Contact: Bing Miller, B.Miller@kempbiotech.com

KAI Research, Inc. -- Booths 242, 243, 143, and 145
KAI Research is a full service contract research organization
supporting clinical studies for the pharmaceutical and Biotech
industries and the National Institutes of Health. KAI provides
clinical trials implementation and operations support including
monitoring statistical analysis and medical writing, clinical data
management using EDC, Pharmacovigilance and safety reporting, and
regulatory support.
Contact: Selma Kunitz, skunitz@kai-research.com

Expression Pathology Incorporated -- Booths 242, 243, 143, and
145
Every surgical and biopsy sample is routinely preserved in
formalin, and tissue collections exist worldwide with well-
documented clinical outcomes.
EPI's /Liquid Tissue(TM)/ proprietary products and services are the
first to enable discovery and validation of protein biomarkers in
such archived tissue by mass spectrometry and high throughput
immunodetection.
Contact: Thomas Guiel, tguiel@expressionpathology.com

Chesapeake PERL -- Booths 242, 243, 143, and 145
Chesapeake PERL is a protein manufacturing company. We exploit
baculovirus expression, using insect larvae as "mini bioreactors".
Our factory is the world's most advanced, automated facility for
mass-rearing insects that allows us to produce high-quality complex
recombinant proteins such as antibodies, virus antigens, specialty
enzymes and kinins from milligram to kilogram scale within a very
short lead-time.
Contact: Catherine E. Vorwald, cvorwald@c-perl.com

MetaMorphix Inc. -- Booths 242, 243, 143, and 145
Founded in 1994 and based in Beltsville, MD, MetaMorphix Inc. is
a life science company dedicated to the discovery and development of
products for the livestock, animal and human health industries. By
drawing on our two fundamental proprietary technologies -- animal
genomics and growth differentiation factors (GDFs) -- we are seeking
to develop products to substantially increase livestock quality and
production efficiency, companion animal health and potentially treat
human muscle degenerative diseases and metabolic disorders.
Contact: Theresa Brady, TBrady@metamorphixinc.com

To find out more about the Maryland Pavilion and to meet the
companies in it, please call Rick Harris, VP of Marketing at the
Tech Council of Maryland at (240) 453-6214 or e-mail him at
rharris@mdhitech.org.

TCM Media Contact: Rick Harris, rharris@mdhitech.org

SOURCE Tech Council of Maryland
Web Site: http://www.mdhitech.org

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech Talent Partnership

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Tuesday, June 07, 2005

Generex Biotechnology Establishes Presence in Europe & the Middle East

Generex Biotechnology Establishes Presence in Europe & the Middle East

Company prepares for further commercialization of Oral-lyn(TM)

Generex Biotechnology Corporation (Nasdaq: GNBT - News), a leader in the area of buccal drug delivery, today announced the establishment of satellite offices in Europe and the Middle East.

In anticipation of the 2005 submission to the Medicines and Healthcare products Regulatory Agency (MHRA) in London of an Oral-lyn(TM) protocol for the commencement of Phase III clinical trials in Europe, Generex has established a satellite office in the United Kingdom from which the Company's European clinical and regulatory development program will be administered. The Company anticipates that its MHRA application for Oral-lyn(TM) Phase III approval will be the cornerstone of its European registration program.

The UK office will be headed by Dr. Munaf Ali, BSc, MSc, PhD, as the Company's Vice-President of Clinical & Regulatory Affairs. Dr. Ali has more than a decade of experience in regulatory affairs and drug development. From 1996 to 1999, Dr. Ali was a principle scientific reviewer at MHRA, including membership in the European Biotech Working Party and CPMP representative for the UK at the European Medicines Evaluation Agency (EMEA). From 1999 to 2003, Dr. Ali was Vice-President of International Regulatory Affairs & Pharmacovigilance and then Global Vice-President of Regulatory Affairs & Pharmacovigilance at Ingenix, Inc., a healthcare information and research company providing a comprehensive line of clinical and cost management solutions, where Dr. Ali provided scientific and regulatory strategic advice for the conduct of clinical trials across many therapeutic areas in 46 different countries. Dr. Ali has been President of Munaf Ali Consultancy Ltd. since 2003.

Oral-lyn(TM) is Generex's proprietary oral insulin formulation, delivered via the Company's proprietary RapidMist(TM) device into, and absorbed by, the buccal mucosa in the mouth (with no lung deposition). Generex believes that Oral-lyn(TM), which was recently approved for commercial sale in Ecuador, provides the opportunity for a significant and beneficial paradigm shift in the treatment of diabetes and its complications by offering a safe, simple, fast, flexible and convenient alternative to prandial insulin injections.

In addition, Generex, with the assistance of local consultants, is aggressively sourcing and evaluating prospective Oral-lyn(TM) licensing opportunities in the Middle East in respect of which the Company is expecting to receive significant nonrefundable, upfront license fees. In order to more effectively and efficiently facilitate the establishment of such arrangements and the consequent product registration initiatives, Generex has established a satellite office in Beirut, Lebanon.

Generex anticipates that, with the assistance of its local consultants, the Beirut office will act as a bridge for the introduction of Oral-lyn(TM) and other new and innovative medical and pharmaceutical technologies and products to the Middle East, a region often overlooked by multinational pharmaceutical concerns. More than 12 million people in the Middle East suffer from diabetes and its complications.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Oral-lyn(TM)), is in various stages of clinical trials around the world.

For more information, visit the Generex Web site at http://www.generex.com.

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward- looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

--------------------------------------------------------------------------------
Source: Generex Biotechnology Corporation

http://www.arizonabiotech.com/
Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
Biotech News
http://www.arizonaentrepreneurs.com/
Arizona Entrepreneurs
http://www.azhttp.com/
Arizona High Tech

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Phoenix, Arizona Biocluster Seeks Business & Research Opportunities With European Biotech Companies

Phoenix, Arizona Biocluster Seeks Business & Research Opportunities With European Biotech Companies

Vibrant Urban Setting Creates Unique Ambiance for 28-Acre Biocenter

PHOENIX, AZ -- 03/23/2005

The City of Phoenix has officially become the nation's newest
biotech cluster with the grand opening of its Downtown Biomedical
Center and worldwide headquarters for TGen (Translational Genomics
Institute) and IGC (International Genomics Consortium). The City of
Phoenix and State of Arizona have invested and laid the foundation
for becoming one of the industry's foremost research centers with
regards to neurogenomics and related research areas of alzheimer's,
autism, cancer, and diabetes. The city seeks to attract biotech and
related companies to Phoenix and Arizona from Europe for business
opportunities in R&D, collaboration, partnering, and office
expansion.

The Phoenix Biomedical Center provides a unique, urban environment
for cutting edge companies to expand offices or open R&D centers.
The $46 million TGen/IGC building forms the foundation of the PBC, a
28-acre development area planned near the epicenter of Copper
Square -- a thriving and rejuvenated section of Phoenix featuring
sports, music, theatre, restaurants and other entertainment and
cultural venues. The futuristic, 173,000-square-foot TGen/IGC
building is owned by the City of Phoenix.

Arizona Governor Janet Napolitano cuts the ribbon to
officially open the new TGen building and Downtown
Phoenix Biomedical Center. (L-R Front Row) Phoenix
Mayor Phil Gordon, Speaker of the House James P.
Weiers, Arizona Governor Janet Napolitano, TGen
President and Scientific Director Jeffrey M. Trent,
and Phoenix Councilman Greg Stanton."Building our biotech industry
is very important for the state's future economic growth and will
benefit all its citizens," said Arizona Governor Janet
Napolitano. "We are committed to investing resources, and fostering
a positive investment climate in partnership with our universities,
to make Arizona more attractive to out of state companies wishing to
open or expand offices here."

"Now that we've completely moved into our state-of-the-art facility,
I'm looking forward to the next stages and milestones we will
accomplish in the scientific community," says Dr. Jeffrey M. Trent,
TGen's President and Scientific Director. "The research conducted
here will be valuable to companies and organizations worldwide."

"In addition to our rich cultural and entertainment venues, Downtown
Phoenix has the resources and infrastructure necessary to attract
and sustain world-class organizations and companies," said Phil
Gordon, Mayor of Phoenix. "We're excited to have TGen, IGC, and
NIDDK in our midst, and we invite biotech companies from out of
state and around the world to investigate the business opportunities
for R&D, collaboration, and expansion that we offer."

Building Grand Opening Features Leaders from Government and
Scientific Community

A ribbon-cutting ceremony will be attended by Arizona State
Governor, Janet Napolitano, City of Phoenix Mayor, Phil Gordon, U.S.
Senator, Jon Kyl, and TGen President & Scientific Director, Dr.
Jeffrey M. Trent. A keynote speech will be delivered by Francis S.
Collins, M.D., Ph.D. Director, National Human Genome Research
Institute. Thousands are expected to attend. The celebration also
includes a Health & Research Fair from 7:30 a.m. - noon with exhibit
booths from more than 40 biotech and related partner organizations.

About the Phoenix Biomedical Center The PBC is the keystone of the
state-wide bioscience initiative and is expected to have a
significant impact on biomedical discoveries, the quality of health
care for Arizona's residents, and the expansion and diversification
of the state's economy. Other planned developments for the PBC area
include the Arizona Biomedical Collaborative (a three university
teaching facility), a College of Medicine, a College of Pharmacy,
and a College of Nursing.

Major Regional Biotech Organizations & Resources

-- Arizona Heart Institute
-- Arizona State University
-- Banner Health
-- Barrow Neurological Institute
-- Mayo Clinic
-- NIDDK
-- Scottsdale Healthcare
-- St. Joseph's Hospital
-- The Biodesign Institute of ASU
-- University of Arizona

Phoenix Region Facts
Population: 3.4 million
Bio-Related Companies: 1,000+
Major Airport: 23 major airlines, 7th busiest airport in
the world
Higher Education: 25 institutions of higher learning, 277,000
enrolled students
Weather: Average temperature 73F. 300+ sunny days a
year
Entertainment: 52 theatres, 40 museums, 200 art galleries,
4 pro
sports teams

About Phoenix

Phoenix is one of the fastest-growing cities in the nation. The
region offers a growing and skilled workforce, a competitive
business environment, easy access to major markets and more. The
city has a wealth of programs and activities to assist businesses,
large and small. Phoenix offers just about everything in the way of
sports, recreation, arts, culture, dining, lodging and financial
opportunities. Because of our beautiful weather, activities can be
enjoyed year-round. The city has won many major awards, including
the Carl Bertelsmann Prize, a prestigious international competition
that recognizes the best-run city government in the world. For more
information about Phoenix and regional biotech related business
opportunities, visit the Web site http://phoenix.gov or call 1-866-
TECH CITY (832-4248) or (602) 534-6122.

Arizona Governor Janet Napolitano shares a laugh with the 1000+
audience of bioindustry professionals attending the grand opening of
the TGen (Translational Genomics Institute) facility and Downtown
Phoenix Biomedical Center. (L-R) Councilmen Greg Stanton and Claude
Mattox, Governor Napolitano. (Front row to right of podium) TGen
President and Scientific Director Jeffrey M. Trent and Francis S.
Collins, M.D., Ph.D., Director, National Human Genome Research
Institute.

SOURCE: City of Phoenix

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Monday, June 06, 2005

[ biotech news ] Junior High School Kids Learn Biotech 101

<a
href="http://www.rednova.com/news/science/154217/junior_high_school_k
ids_learn_biotech_101/">RedNova News - Science - Junior High School
Kids Learn Biotech 101</a>

Junior High School Kids Learn Biotech 101
BREMERTON, Wash. -- A genetic experiment is part of the curriculum
in the classroom of science teacher Cathy Nitchman, a former
research oceanographer.

But the high-tech learning experience doesn't come cheap. The
experiment is part of a science kit that can cost up to $10,000.

Scattered around Nitchman's classroom are all the biotech
paraphernalia in the kit _ micropipets that look like giant plastic
hypodermic needles that the students use to inject chemicals onto
cultures, small jars of chemicals and a large Styrofoam incubator.

Nitchman holds up a little glass bottle to the class. "This plasmid
costs $500," she says, exhorting them to handle the small, DNA-
containing element carefully.

The students will inject the plasmid into a colony of harmless E.
coli bacteria and then "shock" the bacteria into accepting the
foreign DNA into its cell.

If the experiment is successful, the students will have given some
ordinary run-of-the-mill laboratory bacteria two new traits: a gene
that makes a protein to turn the colony blue and a gene for
ampicillin resistance.

"The students are learning how genes can be transferred from one
organism to another," Nitchman says, "and how genes cause traits
such as blue eyes. They are also learning proper laboratory
techniques."

The science kits are provided by the Fred Hutchinson Cancer Research
Center in Seattle. Last year, more than 100 teachers in Washington
used the kits in science classes.

Biotech
Biotech News
Arizona Entrepreneurs
Arizona Tech

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

20 MSc Biotech seats for State students

20 MSc Biotech seats for State students

20 MSc Biotech seats for State students

Varsities have already received 700 applications.

Ahmedabad, June 6: PERTURBED by ‘outside’ students securing admission to M Sc Biotechnology course at the cost of the local students, the various universities of the State have decided to introduce 20 additional seats for the aspiring Gujarat students from the current academic session. What’s more, admission for these ‘extra’ seats will be done on merit only unlike the All-India Common Entrance Test, conducted by the Jawaharlal Nehru University (JNU) for the regular seats.

The Universities have already received 700 applications for these 20 extra seats.

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Report Shows Biotech Booming in Greater Philadelphia

Report Shows Biotech Booming in Greater Philadelphia

19th Annual Ernst & Young Industry Survey Calls Greater Philadelphia
A Top 10 Region for Biotech

PHILADELPHIA,

Select Greater Philadelphia applauded the announcement that the
Greater Philadelphia region ranks in the top 10 in biotech business,
according to the new Ernst & Young industry report. The report
showcases the region's growing stature as a "biotech boomtown" as
final preparations are underway for the BIO 2005 convention, to be
held in Philadelphia June 19 - 22.

The 19th annual Ernst & Young industry report showed Greater
Philadelphia had 13 public biotech companies in 2004. That's up 26
percent from the previous year, and positions Greater Philadelphia
as the number 10 region in terms of public biotech firms.

E&Y counted a combined 68 public and private biotech companies in the
region, also ranking Greater Philadelphia 10th.

"Philadelphia has always been a major player in the biotech world,
and I don't see that changing," Mike Hildrith, Americas
Biotechnology director at Ernst & Young told The Philadelphia
Inquirer. "There is an active venture capital community, a robust
academic research community and entrepreneurial spirit."

The report also shows that Greater Philadelphia ranks:

-- 9th in biotech market value ($6.2 Billion)
-- 8th in biotech revenue ($1.2 Billion)
-- 8th in short-term investments ($1.5 Billion)

The 11-county Greater Philadelphia region stacks up favorably
against other regions in the Top 10 when you consider that many of
the other regions are considerably larger. For instance, the New
England region includes five entire states; the Southeast region is
comprised of eight states.

Additionally, Ernst & Young did not count pharmaceutical
companies, many of which are heavily invested in biotech research
and development. Eighty of the world's largest pharmaceutical
companies have a presence in the region.

"When you consider that we are being compared to regions so much
larger in size, it's easy to see that Greater Philadelphia is a
hotbed of biotech activity," said Jim Shannon, Chief Marketing
Officer for Select Greater Philadelphia. "The biosciences industry
is a critical segment of our regional economy, and a major reason
why this region is thriving."

Select Greater Philadelphia is a business marketing organization
dedicated to building the economy of the tri-state Greater
Philadelphia region by enhancing the region's profile and image in
order to attract and retain businesses. It is a private, nonprofit
organization.

Select Greater Philadelphia markets the region nationally and
globally in order to establish Greater Philadelphia as a top-tier
place to do business.

The Greater Philadelphia region encompasses Southeastern
Pennsylvania, Southern New Jersey and Northern Delaware.

SOURCE Select Greater Philadelphia

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Sunday, June 05, 2005

[ biotech news ] Why Biotech Stocks Are Sedated

<a
href="http://www.businessweek.com/magazine/content/05_24/b3937006_mz001.htm">Why Biotech Stocks Are Sedated</a>

Why Biotech Stocks Are Sedated

Judging from Genentech Inc.'s (DNA ) stellar performance on Wall
Street this year, biotech might seem like a can't-miss investing
opportunity. Since January, Genentech's shares have rocketed 49.2%,
to $81.25, fueled by positive news about its drugs to treat cancer
and macular degeneration, a major cause of blindness. A strong
showing from a sector leader often sends capital flooding into
similar companies, lifting the whole group. Advertisement

Elsewhere, though, investors are spitting out biotech stocks as if
they were spoiled medicine. The American Stock Exchange
Biotechnology Index, which counts Genentech among its members, has
risen just 1.1% since January. The broader NASDAQ Biotechnology
Index is down 11.7%. Even sexy-sounding biotech upstarts are
struggling to find love on Wall Street: The 40 or so that have gone
public since 2003 have dropped an average of 7% since their IPOs,
according to Burrill & Co., a merchant banker covering life sciences.

Arizona Biotech
Biotech News
Famous Quotes
Arizona Entrepreneurs
Arizona High Tech

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Thursday, June 02, 2005

[ biotech news ] Conference Highlights N.C.'S Biotech Community; Biotech 2005 Draws Experts from

Conference Highlights N.C.'S Biotech Community; Biotech 2005 Draws
Experts from Medicine, Finance and Government to Explore Future
Potential of Life Science Sector

RESEARCH TRIANGLE PARK, N.C. May 25, 2005 - The Council for
Entrepreneurial Development (CED), along with the North Carolina
Biotechnology Center, the North Carolina Biosciences Organization
(NCBIO) and the Biotechnology Industry Organization (BIO), hosted
the 14th annual Biotech conference on Tuesday and Wednesday with
more than 800 people participating in total. Held at the RTP's
Sheraton Imperial Hotel and Convention Center, Biotech 2005: Fusing
Science, Technology and Industry Leadership showcased the state's
position as a global player in the life science sector.

The conference kicked off Tuesday afternoon with comments from Dr.
Henri Meier, Chairman of the Board of Directors, HBM Partners AG and
HBM BioVentures AG. Dr. Meier shared his experience investing
globally in life science companies. He noted that North Carolina was
uniquely positioned to take advantage of biotechnology's explosive
growth moving forward.

"North Carolina is a great place to do business. I can't imagine a
more inviting place to do a deal," Dr. Meier told Biotech 2005
attendees. "North Carolina must continue to leverage its collegial
spirit and collaborative nature of doing business."

Dr. Victor Dzau, Chancellor for Health Affairs, Duke University and
President and CEO, Duke University Health System, also spoke Tuesday
afternoon at the conference. Dr. Dzau emphasized the importance of
bold, strategic collaborations to improve the pipeline of innovation
and commercialization.

On Wednesday morning, the conference featured opening remarks from
Leslie Alexandre, President and CEO of the N.C. Biotechnology
Center; Lieutenant Governor Beverly Perdue; and Dr. Tanja Popovic,
Acting Associate Director for Science, The Centers for Disease
Control and Prevention (CDC).

Following these comments, the conference offered six concurrent
panels that highlighted trends in late-stage financing, early-stage
financing, global biotech, government partnerships, personalized
medicines and technology convergence.

During lunch on Wednesday, Walter E. Daniels of Daniels Daniels &
Verdonik received the 3rd annual Charles Hamner Leadership Award in
recognition of extraordinary contributions and service in the
region's life science sector.

David Malakoff, technology and science correspondent for National
Public Radio (NPR), wrapped up the conference with a luncheon
keynote address. Through humorous anecdotes, Malakoff explained the
implications of fragmented media, the public's perception of media,
journalists' role as advocates/critics, and the occasional "clash of
cultures" between scientists and journalists.

After Malakoff's comments, Biotech 2005 Conference Co-Chair Murray
Spruill of Alston & Bird encouraged conference attendees to work
diligently to support life sciences in North Carolina.

"I'm proud of the biotech community in North Carolina," Spruill
said. "I challenge everyone to go out and continue to do great
things for North Carolina's life science economy."

About CED: The Council for Entrepreneurial Development, located in
Research Triangle Park, NC, is a private, non-profit organization
formed in 1984 to stimulate the creation and growth of high-impact
companies in the greater Research Triangle region. CED provides
education, mentoring and capital formation resources to new and
existing high-growth entrepreneurs through annual conferences,
seminars, workshops and monthly programs on entrepreneurial
management and finance. CED, which celebrates its 20th anniversary
in 2004, is the largest entrepreneurial support organization in the
nation with more than 3,500 members representing 1,000
entrepreneurial companies, financiers and professional firms.
www.cednc.org

About the North Carolina Biotechnology Center: The North Carolina
Biotechnology Center is a private, non-profit corporation funded
primarily by the state's General Assembly. Its mission is to provide
long-term economic and societal benefits to North Carolina by
supporting biotechnology research, business and education statewide.
www.ncbiotech.org

About the North Carolina Biosciences Organization: NCBIO is a trade
organization promoting the development of the biosciences industry
in North Carolina. NCBIO provides cost-effective, organized
legislative and advocacy efforts on behalf of the industry at the
state and federal levels.

About the Biotechnology Industry Organization: The Biotechnology
represents more than 1,000 biotechnology companies, academic
institutions, state biotechnology centers and related organizations
in all 50 U.S. states and 33 other nations. BIO members are involved
in the research and development of healthcare, agricultural,
industrial and environmental biotechnology products. www.bio.org

Biotech
Biotech
Entrepreneurs
High Tech

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Wednesday, June 01, 2005

[ biotech news ] Ribomed Recognized by Frost & Sullivan for Excellence in Biological Detection

Ribomed's innovative technology has been recognized by the leading
market research firm, Frost & Sullivan, with its award to Ribomed of
the Biological Detection Technologies Excellence in Research of the
Year Award for 2005.

Ribomed Recognized by Frost & Sullivan for Excellence in Biological
Detection Technologies Research

Naples, Fla. May 25, 2005 Frost & Sullivan will present Ribomed
Biotechnologies, Inc. with
the 2005 Biological Detection Technologies Excellence in Research of
the Year Award at
tonight's Excellence in Industrial Technologies Banquet.
Ribomed receives the Award for its excellence in research and
development (R&D) and for its
introduction of the Abscription® process that detects both disease
cells and germs that serve as
biological warfare agents.
Abscription, a contraction of abortive transcription, is a rapid,
robust, isothermal, polymerase
chain reaction (PCR)-free method for detecting and quantifying
target proteins and nucleic acids.
It is an integral part of Ribomed's RiboMaker® Detection System.
Abscription's development was driven by four major requirements in
clinical, and later, biological
defense detection systems. The first was the inadequacy of
conventional detection systems in
terms of time, efficiency, and practicality. The second was the
rising cost of healthcare, which
created a need to improve diagnosis and drug development.
The third factor was the U.S. Government's apprehension about
national security from biological
attacks both at home and abroad. Lastly, the growth of molecular
genetics promotes molecular
detection of diseases and the development of disease- and patient-
specific drugs.
"Abscription uses the reiterative synthesis of short RNA Abscripts®,
which are produced by the
RiboMaker® Abscriptase® enzyme, to rapidly generate thousands of
detectable and quantifiable
signals per target per minute," says Frost & Sullivan research
analyst Michael Valenti.
"Abscripts® are generated from an artificially created start site
for Abscription, called an
Abscriptase ® Promoter Cassette (APC)."
Modular RiboMaker® APCs can be linked to targeted molecules such as
RNA, DNA, or protein,
and, since Abscription is linear, the amount of Abscripts® generated
is directly proportional to the
number of target molecules present.
Abscripts® can be tagged with reporters, affinity tags, or haptens
during the Abscription process
by incorporating Ribomed's proprietary tagged Ribonucleotide analogs
(RiboLogs®). They are
then fed into several different secondary signaling systems, leading
to the rapid production of
millions of signals per target. Moreover, Abscription is highly
conducive to multiplexing, and can
create more than 20 APCs, each producing a unique product.
By being able to identify infectious agents accurately in real time
using the Abscription-based
RiboMaker detection tests, physicians can treat patients at their
point-of-care, saving 72 hours of
culturing to pick an appropriate treatment.
"This time saving can be critical in determining whether persons are
victims of a biological attack
and in devising the most appropriate method of treating them," notes
Valenti. "It has also sparked
the funding by several agencies of the federal government in
bioterrorism applications."
The National Institutes of Health (NIH/NCI, NIAID), the U.S.
Department of Defense (DARPA),
and the Department of Homeland Security (HSARPA) have supported the
development of
Abscription.
"Ribomed continues to exploit the robustness of the Abscription®
process by developing a bloodbased
test for rapid development of vaccines to deadly viruses and
bacteria," observes Valenti.
7550 IH 10 West, Suite 400
San Antonio, TX 78229
Tel. 210.348.1000 Fax 210.348.1003
www.frost.com
"The company has a novel approach to identifying both airborne and
blood-transmitted pathogens
and early disease biomarkers, and has proved its superiority in R&D
with its revolutionary
technologies for biological detection."
Frost & Sullivan presents its Excellence in Research of the Year
Award to the company that has
carried out new, disruptive research in its industry. The Award
recognizes a company's R&D
program that Frost & Sullivan expects will bring significant
contributions to the industry in terms of
adoption, change, and competitive posture. The results of this
research may already have altered
or will potentially impact certain market sectors.
Held in Naples, Fla., the Frost & Sullivan Excellence in Industrial
Technologies Awards Banquet
honors world-class companies for outstanding performance and
achievements in their industries.
An annual event, the banquet recognizes the quality and merit of
distinguished individuals and
companies.
About Ribomed Biotechnologies, Inc.
Ribomed Biotechnologies, Inc. is a molecular diagnostics company
developing rapid, specific and
robust tests for the early detection and characterization of
diseases and their causative agents,
and the screening of drugs for treatment. Ribomed is dedicated to
improving the quality of life
through early disease detection, noninvasive monitoring and patient-
specific therapies.
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been
partnering with clients to support
the development of innovative strategies for more than 40 years. The
company's industry
expertise integrates growth consulting, growth partnership services
and corporate management
training to identify and develop opportunities. Frost & Sullivan
serves an extensive clientele that
includes Global 1000 companies, emerging companies, and the
investment community, by
providing comprehensive industry coverage that reflects a unique
global perspective and
combines ongoing analysis of markets, technologies, econometrics,
and demographics. For
more information, visit www.frost.com.
Contact:
Stacie Jones
210.247.2450
Stacie.jones @ frost.com

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech

Biotech News 0 comments

Subscribe to biotech-news